https://trial.medpath.com/news/protara-therapeutics-announces-fast-track-designation-for-intravenous-choline-chloride 2024-10-21T12:58:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protara-therapeutics-announces-fast-track-designation-for-intravenous-choline-chloride 2024-10-21T12:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/october-21-2024-best-icu-and-chat-4-heart-health-have-updated-study-snapshots 2024-10-21T12:50:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-21-2024-best-icu-and-chat-4-heart-health-have-updated-study-snapshots 2024-10-21T12:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/inovio-announces-new-data-at-scientific-conferences-for-lead-candidate-ino-3107-as-a 2024-10-21T12:39:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inovio-announces-new-data-at-scientific-conferences-for-lead-candidate-ino-3107-as-a 2024-10-21T12:39:50+00:00 weekly 0.7 https://trial.medpath.com/news/veru-to-present-at-obesityweek-meta-analysis-of-4-previous-randomized-clinical-trials 2024-10-21T12:37:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veru-to-present-at-obesityweek-meta-analysis-of-4-previous-randomized-clinical-trials 2024-10-21T12:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-announces-ketamir-2-outperforms-current-fda-approved-newswire 2024-10-21T12:25:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-announces-ketamir-2-outperforms-current-fda-approved-newswire 2024-10-21T12:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-to-host-participate-in-two-public-webinars-during-october-stock-titan 2024-10-21T12:12:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantern-pharma-to-host-participate-in-two-public-webinars-during-october-stock-titan 2024-10-21T12:12:29+00:00 weekly 0.7 https://trial.medpath.com/news/nevada-king-intercepts-9-1m-of-4-32-g-t-au-extending-mineralization-420 2024-10-21T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nevada-king-intercepts-9-1m-of-4-32-g-t-au-extending-mineralization-420 2024-10-21T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-to-present-at-the-thinkequity-conference-on-october-30th-globenewswire 2024-10-21T12:06:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/windtree-to-present-at-the-thinkequity-conference-on-october-30th-globenewswire 2024-10-21T12:06:59+00:00 weekly 0.7 https://trial.medpath.com/news/biomed-industries-presents-phase-i-results-of-its-oral-quadruple-receptor-agonist-na-931 2024-10-21T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomed-industries-presents-phase-i-results-of-its-oral-quadruple-receptor-agonist-na-931 2024-10-21T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trials-of-pd-1-pd-l1-inhibitors-in-nmibc-urology-times 2024-10-21T12:05:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trials-of-pd-1-pd-l1-inhibitors-in-nmibc-urology-times 2024-10-21T12:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-announces-fda-acceptance-of-new-drug-globenewswire 2024-10-21T12:02:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenz-therapeutics-announces-fda-acceptance-of-new-drug-globenewswire 2024-10-21T12:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clamps-partial-hold-on-phase-iii-trial-of-biontech-oncoc4-s-nsclc-therapy-yahoo 2024-10-21T11:41:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clamps-partial-hold-on-phase-iii-trial-of-biontech-oncoc4-s-nsclc-therapy-yahoo 2024-10-21T11:41:48+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-reports-positive-phase-2-results-for-cdi-treatment-ibezapolstat-by-investing-com 2024-10-21T11:41:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurx-reports-positive-phase-2-results-for-cdi-treatment-ibezapolstat-by-investing-com 2024-10-21T11:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-presents-positive-data-from-the-phase-ii-study-of-subretinal-abbv-rgx-314-in 2024-10-21T11:14:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenxbio-presents-positive-data-from-the-phase-ii-study-of-subretinal-abbv-rgx-314-in 2024-10-21T11:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/fibrobiologics-charles-river-agree-on-therapies-manufacture-pharmaceutical-technology 2024-10-21T11:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fibrobiologics-charles-river-agree-on-therapies-manufacture-pharmaceutical-technology 2024-10-21T11:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/nuclidium-s-copper-based-radiotracer-shows-enhanced-imaging-performance-in-first-prostate-cancer-patient 2024-10-21T10:59:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuclidium-s-copper-based-radiotracer-shows-enhanced-imaging-performance-in-first-prostate-cancer-patient 2024-10-21T10:59:39+00:00 weekly 0.7 https://trial.medpath.com/news/news-engineered-polymers-show-promise-for-systemic-mrna-delivery-to-lungs 2024-10-21T10:58:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-engineered-polymers-show-promise-for-systemic-mrna-delivery-to-lungs 2024-10-21T10:58:17+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw171-biospace 2024-10-21T10:41:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw171-biospace 2024-10-21T10:41:02+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-frailty-scale-score-is-a-predictor-of-short-mid-and-long-term-mortality-in-critically-ill 2024-10-21T10:35:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-frailty-scale-score-is-a-predictor-of-short-mid-and-long-term-mortality-in-critically-ill 2024-10-21T10:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-receives-positive-chmp-opinions-for-tevimbra-r-as-a-first-line-treatment-via-ritzau 2024-10-21T10:27:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-receives-positive-chmp-opinions-for-tevimbra-r-as-a-first-line-treatment-via-ritzau 2024-10-21T10:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-might-spot-women-in-labor-at-risk-for-preeclampsia 2024-10-21T10:08:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-test-might-spot-women-in-labor-at-risk-for-preeclampsia 2024-10-21T10:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/tenaya-therapeutics-cleared-to-move-onto-higher-dose-cohort-in-trial-of-hypertrophic 2024-10-21T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenaya-therapeutics-cleared-to-move-onto-higher-dose-cohort-in-trial-of-hypertrophic 2024-10-21T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/after-shingles-damaged-her-vision-this-former-eye-surgeon-looked-for-a-way-to-keep-it-from 2024-10-21T08:32:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-shingles-damaged-her-vision-this-former-eye-surgeon-looked-for-a-way-to-keep-it-from 2024-10-21T08:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/senolytics-to-slow-progression-of-sepsis-stop-sepsis-in-elderly-patients-study-protocol-trials 2024-10-21T08:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senolytics-to-slow-progression-of-sepsis-stop-sepsis-in-elderly-patients-study-protocol-trials 2024-10-21T08:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/astex-pharmaceuticals-announce-key-data-presentations-at-the-36th-eortc-nci-aacr 2024-10-21T08:07:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astex-pharmaceuticals-announce-key-data-presentations-at-the-36th-eortc-nci-aacr 2024-10-21T08:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/new-podcast-kidney-compass-launches-to-navigate-complex-landscape-of-nephrology-clinical-trials 2024-10-21T08:00:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-podcast-kidney-compass-launches-to-navigate-complex-landscape-of-nephrology-clinical-trials 2024-10-21T08:00:52+00:00 weekly 0.7 https://trial.medpath.com/news/dr-john-conibear-on-the-evolution-of-durvalumab-in-nsclc-care 2024-10-21T07:52:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-john-conibear-on-the-evolution-of-durvalumab-in-nsclc-care 2024-10-21T07:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-ten-new-medicines-medwatch 2024-10-21T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-ten-new-medicines-medwatch 2024-10-21T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/lindis-biotech-receives-positive-chmp-opinion-for-korjuny-r-catumaxomab-in-eqs-news 2024-10-21T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lindis-biotech-receives-positive-chmp-opinion-for-korjuny-r-catumaxomab-in-eqs-news 2024-10-21T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/ananda-developments-epilepsy-trials-research-tree 2024-10-21T06:22:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ananda-developments-epilepsy-trials-research-tree 2024-10-21T06:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/asds-2024-new-phase-iii-ready-4-data-demonstrate-long-term-safety-and-efficacy-of 2024-10-21T06:01:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asds-2024-new-phase-iii-ready-4-data-demonstrate-long-term-safety-and-efficacy-of 2024-10-21T06:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-technologies-transform-quality-assurance-in-emerging-cell-and-gene-therapies 2024-10-21T05:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advanced-technologies-transform-quality-assurance-in-emerging-cell-and-gene-therapies 2024-10-21T05:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/elevar-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-rivoceranib-in-combination-with-camrelizumab-as-a-first-line-systemic-treatment-for-unresectable-hepatocellular-carcinoma 2024-10-21T05:10:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevar-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-rivoceranib-in-combination-with-camrelizumab-as-a-first-line-systemic-treatment-for-unresectable-hepatocellular-carcinoma 2024-10-21T05:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-announces-fda-acceptance-of-new-drug-application-for-lnz100-for-the-treatment-of-presbyopia 2024-10-21T05:10:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenz-therapeutics-announces-fda-acceptance-of-new-drug-application-for-lnz100-for-the-treatment-of-presbyopia 2024-10-21T05:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/understanding-alternative-pathways-to-access-non-fda-approved-medications-a-comprehensive-review 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/understanding-alternative-pathways-to-access-non-fda-approved-medications-a-comprehensive-review 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/washington-university-s-clinical-trial-development-program-shows-success-in-training-future-investigators 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/washington-university-s-clinical-trial-development-program-shows-success-in-training-future-investigators 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blue-lake-biotechnology-and-cyanvac-announce-presentation-on-intranasal-vaccine 2024-10-21T04:21:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blue-lake-biotechnology-and-cyanvac-announce-presentation-on-intranasal-vaccine 2024-10-21T04:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/hyperbaric-oxygen-therapy-in-the-treatment-of-late-onset-hemorrhagic-cystitis-after 2024-10-21T04:07:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hyperbaric-oxygen-therapy-in-the-treatment-of-late-onset-hemorrhagic-cystitis-after 2024-10-21T04:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-eyepoint-s-eyp-1901-proves-non-inferiority-to-aflibercept-in-davio-2 2024-10-21T02:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-eyepoint-s-eyp-1901-proves-non-inferiority-to-aflibercept-in-davio-2 2024-10-21T02:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-rezolute-s-rz-402-shows-promising-phase-iia-results-in-dme-patients 2024-10-21T01:37:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-rezolute-s-rz-402-shows-promising-phase-iia-results-in-dme-patients 2024-10-21T01:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/durga-borkar-md-phase-2-results-of-onl1204-for-rhegmatogenous-retinal-detachment 2024-10-21T01:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/durga-borkar-md-phase-2-results-of-onl1204-for-rhegmatogenous-retinal-detachment 2024-10-21T01:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-announces-first-in-human-phase-i-study-of-imp761-progresses-to-dose 2024-10-21T00:58:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-announces-first-in-human-phase-i-study-of-imp761-progresses-to-dose 2024-10-21T00:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/aprogen-a-company-specializing-in-antibody-drug-development-announced-on-the-21st-that 2024-10-21T00:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aprogen-a-company-specializing-in-antibody-drug-development-announced-on-the-21st-that 2024-10-21T00:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/recruitment-restarts-in-accent-pancreatic-cancer-trial-biomelbourne-network 2024-10-21T00:38:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recruitment-restarts-in-accent-pancreatic-cancer-trial-biomelbourne-network 2024-10-21T00:38:28+00:00 weekly 0.7 https://trial.medpath.com/news/everest-medicines-announces-taiwan-tfda-approval-of-nefecon-r-for-the-treatment-of 2024-10-21T00:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/everest-medicines-announces-taiwan-tfda-approval-of-nefecon-r-for-the-treatment-of 2024-10-21T00:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/glecirasib-pancreatic-cancer-indication-received-orphan 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glecirasib-pancreatic-cancer-indication-received-orphan 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accelerated-approval-and-confirmatory-trials-timing-is-everything 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accelerated-approval-and-confirmatory-trials-timing-is-everything 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-biopharmaceuticals-boosts-confidence-with-phase-3-plans-tipranks-com 2024-10-20T23:49:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paradigm-biopharmaceuticals-boosts-confidence-with-phase-3-plans-tipranks-com 2024-10-20T23:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/pursuecare-revives-fda-approved-digital-therapeutics-for-addiction-treatment 2024-10-20T23:18:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pursuecare-revives-fda-approved-digital-therapeutics-for-addiction-treatment 2024-10-20T23:18:56+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-clinical-trial-for-treating-spinal-cord-injury-griffith-news 2024-10-20T23:18:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-first-clinical-trial-for-treating-spinal-cord-injury-griffith-news 2024-10-20T23:18:50+00:00 weekly 0.7 https://trial.medpath.com/news/pyc-therapeutics-gains-fda-approval-for-orphan-drug-tipranks-com 2024-10-20T22:54:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pyc-therapeutics-gains-fda-approval-for-orphan-drug-tipranks-com 2024-10-20T22:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/woman-finds-hope-in-new-ms-treatment-wvir 2024-10-20T22:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/woman-finds-hope-in-new-ms-treatment-wvir 2024-10-20T22:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/roger-a-goldberg-md-pooled-visual-function-data-of-nt-501-for-mactel-hcplive 2024-10-20T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roger-a-goldberg-md-pooled-visual-function-data-of-nt-501-for-mactel-hcplive 2024-10-20T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/understanding-the-nuances-of-the-rsv-maternal-vaccine-and-monoclonal-antibody-for-the 2024-10-20T21:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/understanding-the-nuances-of-the-rsv-maternal-vaccine-and-monoclonal-antibody-for-the 2024-10-20T21:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-developments-in-mrna-and-car-t-cell-therapies-reshape-cancer-treatment-landscape 2024-10-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-developments-in-mrna-and-car-t-cell-therapies-reshape-cancer-treatment-landscape 2024-10-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-and-survival-of-non-metastatic-small-cell-carcinoma-of-the-bladder-from-multiple 2024-10-20T20:47:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-and-survival-of-non-metastatic-small-cell-carcinoma-of-the-bladder-from-multiple 2024-10-20T20:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/low-intensity-shockwave-therapy-plasma-injections-efficacious-for-erectile-dysfunction 2024-10-20T20:20:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-intensity-shockwave-therapy-plasma-injections-efficacious-for-erectile-dysfunction 2024-10-20T20:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/aft-enters-late-stage-r-d-agreement-for-a-novel-injectable-nzx 2024-10-20T19:45:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aft-enters-late-stage-r-d-agreement-for-a-novel-injectable-nzx 2024-10-20T19:45:40+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-efgartigimod-ph20-efficacious-in-patients-with-cidp-previously-treated 2024-10-20T19:06:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-efgartigimod-ph20-efficacious-in-patients-with-cidp-previously-treated 2024-10-20T19:06:19+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-explore-how-a-community-practice-implemented-bispecific-antibody 2024-10-20T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-explore-how-a-community-practice-implemented-bispecific-antibody 2024-10-20T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-injectable-endothelial-cell-therapy-shows-promise-for-improving-vision-and 2024-10-20T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-injectable-endothelial-cell-therapy-shows-promise-for-improving-vision-and 2024-10-20T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/can-sharks-cure-cancer-uw-madison-research-shows-positive-advancements-wmtv 2024-10-20T17:29:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-sharks-cure-cancer-uw-madison-research-shows-positive-advancements-wmtv 2024-10-20T17:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/flt3-inhibitor-gilteritinib-may-also-be-effective-as-alk-inhibitor-in-aml 2024-10-20T16:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/flt3-inhibitor-gilteritinib-may-also-be-effective-as-alk-inhibitor-in-aml 2024-10-20T16:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-two-year-clinical-feasibility-trial-outcomes-for-a-dual-optic-iol-system-for-the 2024-10-20T16:07:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-two-year-clinical-feasibility-trial-outcomes-for-a-dual-optic-iol-system-for-the 2024-10-20T16:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/oral-treatment-aims-to-reduce-ga-progression-by-slowing-vitamin-a-dimerization-healio 2024-10-20T15:35:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-treatment-aims-to-reduce-ga-progression-by-slowing-vitamin-a-dimerization-healio 2024-10-20T15:35:31+00:00 weekly 0.7 https://trial.medpath.com/news/trs01-drops-display-favorable-clinical-profile-for-non-infectious-uveitis-hcplive 2024-10-20T15:17:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trs01-drops-display-favorable-clinical-profile-for-non-infectious-uveitis-hcplive 2024-10-20T15:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-myopic-lasik-performed-using-a-novel-excimer-laser-ophthalmology-times 2024-10-20T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-myopic-lasik-performed-using-a-novel-excimer-laser-ophthalmology-times 2024-10-20T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/hallmarks-of-a-genomically-distinct-subclass-of-head-and-neck-cancer-nature 2024-10-20T14:39:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hallmarks-of-a-genomically-distinct-subclass-of-head-and-neck-cancer-nature 2024-10-20T14:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-new-gene-therapy-shows-promise-for-treatment-of-retinitis-pigmentosa 2024-10-20T14:18:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-new-gene-therapy-shows-promise-for-treatment-of-retinitis-pigmentosa 2024-10-20T14:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/ctdna-clearance-confers-responses-to-radiation-in-gynecologic-malignancies 2024-10-20T14:09:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ctdna-clearance-confers-responses-to-radiation-in-gynecologic-malignancies 2024-10-20T14:09:54+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-clinical-trials-of-travoprost-ophthalmology-times-europe 2024-10-20T14:05:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-clinical-trials-of-travoprost-ophthalmology-times-europe 2024-10-20T14:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-jabs-for-unemployed-not-dystopian-says-wes-streeting-bbc 2024-10-20T13:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-jabs-for-unemployed-not-dystopian-says-wes-streeting-bbc 2024-10-20T13:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/cch-appears-safe-efficacious-in-peyronie-disease-with-ventral-curvature-urology-times 2024-10-20T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cch-appears-safe-efficacious-in-peyronie-disease-with-ventral-curvature-urology-times 2024-10-20T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/low-blood-s-methyl-5-thioadenosine-is-associated-with-postoperative-delayed-nature 2024-10-20T12:46:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-blood-s-methyl-5-thioadenosine-is-associated-with-postoperative-delayed-nature 2024-10-20T12:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/foresee-pharmaceuticals-announces-preliminary-results-from-a-phase-1-clinical-trial 2024-10-20T12:36:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-announces-preliminary-results-from-a-phase-1-clinical-trial 2024-10-20T12:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/national-fellows-forum-showcases-next-generation-of-lung-cancer-clinicians-onclive 2024-10-20T12:05:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-fellows-forum-showcases-next-generation-of-lung-cancer-clinicians-onclive 2024-10-20T12:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/philadelphia-hospitals-test-new-strategy-for-tranq-dope-withdrawal-ems1 2024-10-20T12:04:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philadelphia-hospitals-test-new-strategy-for-tranq-dope-withdrawal-ems1 2024-10-20T12:04:38+00:00 weekly 0.7 https://trial.medpath.com/news/hospital-recruits-five-tiny-babies-for-feeding-study-bbc 2024-10-20T11:52:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hospital-recruits-five-tiny-babies-for-feeding-study-bbc 2024-10-20T11:52:40+00:00 weekly 0.7 https://trial.medpath.com/news/letter-collins-goes-above-and-beyond-for-alzheimer-s-patients-the-portland-press-herald 2024-10-20T11:08:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/letter-collins-goes-above-and-beyond-for-alzheimer-s-patients-the-portland-press-herald 2024-10-20T11:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/how-bad-is-this-news-for-novavax 2024-10-20T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-bad-is-this-news-for-novavax 2024-10-20T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-study-demonstrates-the-first-successful-clinical-application-of-antifibrotic-therapy-for-breast-cancer 2024-10-20T09:10:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-study-demonstrates-the-first-successful-clinical-application-of-antifibrotic-therapy-for-breast-cancer 2024-10-20T09:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/study-identifies-approaches-to-address-patient-fears-regarding-jak-inhibitor-safety 2024-10-20T09:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-identifies-approaches-to-address-patient-fears-regarding-jak-inhibitor-safety 2024-10-20T09:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/there-is-a-rare-disease-called-idiopathic-pulmonary-fibrosis-ipf-in-which-the-lungs-slowly-harden 2024-10-20T08:28:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/there-is-a-rare-disease-called-idiopathic-pulmonary-fibrosis-ipf-in-which-the-lungs-slowly-harden 2024-10-20T08:28:24+00:00 weekly 0.7 https://trial.medpath.com/news/expert-takeaway-from-wclc-congress-highlights-innovative-acd-showing-promise-in-sclc 2024-10-20T07:02:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-takeaway-from-wclc-congress-highlights-innovative-acd-showing-promise-in-sclc 2024-10-20T07:02:06+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-boosts-heart-health-weight-loss-but-may-lead-to-gut-problems 2024-10-20T05:25:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-boosts-heart-health-weight-loss-but-may-lead-to-gut-problems 2024-10-20T05:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-clinical-efficacy-endpoints-from-the-phase-3-canopy-study-evaluating-pemivibart 2024-10-20T02:23:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invivyd-clinical-efficacy-endpoints-from-the-phase-3-canopy-study-evaluating-pemivibart 2024-10-20T02:23:31+00:00 weekly 0.7 https://trial.medpath.com/news/distinct-molecular-profiles-and-shared-drug-vulnerabilities-in-pancreatic-metastases-of-renal 2024-10-20T01:08:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/distinct-molecular-profiles-and-shared-drug-vulnerabilities-in-pancreatic-metastases-of-renal 2024-10-20T01:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/pulsed-shortwave-therapy-did-not-reduce-pain-scores-or-opioid-consumption-after-surgery 2024-10-19T23:37:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulsed-shortwave-therapy-did-not-reduce-pain-scores-or-opioid-consumption-after-surgery 2024-10-19T23:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-approved-vorasidenib-for-idh-mutant-gliomas-survivornet 2024-10-19T23:09:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fda-approved-vorasidenib-for-idh-mutant-gliomas-survivornet 2024-10-19T23:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/kerala-joins-icmr-s-clinical-trial-for-indigenous-dengue-vaccine-the-south-first 2024-10-19T23:09:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kerala-joins-icmr-s-clinical-trial-for-indigenous-dengue-vaccine-the-south-first 2024-10-19T23:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/1-reason-to-buy-eli-lilly-stock-hand-over-fist-right-now-the-globe-and-mail 2024-10-19T22:37:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/1-reason-to-buy-eli-lilly-stock-hand-over-fist-right-now-the-globe-and-mail 2024-10-19T22:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/tuhura-biosciences-announces-completion-of-merger-transaction-with-kintara-therapeutics 2024-10-19T21:29:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tuhura-biosciences-announces-completion-of-merger-transaction-with-kintara-therapeutics 2024-10-19T21:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/comparing-anti-tau-antibodies-under-clinical-trials-and-their-epitopes-on-tau-pathologies 2024-10-19T20:30:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparing-anti-tau-antibodies-under-clinical-trials-and-their-epitopes-on-tau-pathologies 2024-10-19T20:30:59+00:00 weekly 0.7 https://trial.medpath.com/news/professor-matt-dun-to-be-awarded-australian-society-for-medical-research-medal-hmri 2024-10-19T18:41:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/professor-matt-dun-to-be-awarded-australian-society-for-medical-research-medal-hmri 2024-10-19T18:41:59+00:00 weekly 0.7 https://trial.medpath.com/news/elevatum-study-s-reason-to-be-underrepresentation-in-clinical-trials-aao-2024 2024-10-19T18:22:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevatum-study-s-reason-to-be-underrepresentation-in-clinical-trials-aao-2024 2024-10-19T18:22:57+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-the-efficacy-of-support-groups-in-the-metaverse-for-ukrainian-refugees-trials 2024-10-19T17:34:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-the-efficacy-of-support-groups-in-the-metaverse-for-ukrainian-refugees-trials 2024-10-19T17:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/asciminib-has-superior-response-rates-in-cml-oncology-nursing-news 2024-10-19T17:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asciminib-has-superior-response-rates-in-cml-oncology-nursing-news 2024-10-19T17:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-reveals-minimal-cognitive-gains-from-antipsychotic-drugs-medical-xpress 2024-10-19T16:44:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-reveals-minimal-cognitive-gains-from-antipsychotic-drugs-medical-xpress 2024-10-19T16:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/complete-consolidative-radiotherapy-may-have-survival-benefits-in-es-sclc 2024-10-19T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/complete-consolidative-radiotherapy-may-have-survival-benefits-in-es-sclc 2024-10-19T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/a-novel-approach-to-chronic-gvhd-with-axatilimab-dr-daniel-wolff 2024-10-19T15:44:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-novel-approach-to-chronic-gvhd-with-axatilimab-dr-daniel-wolff 2024-10-19T15:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/gvhd-cannot-be-wholly-prevented-so-effective-treatments-are-needed-says-dr-daniel-wolff 2024-10-19T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gvhd-cannot-be-wholly-prevented-so-effective-treatments-are-needed-says-dr-daniel-wolff 2024-10-19T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-nicotine-inhaler-for-smoking-cessation-moves-to-trial-phase-kfyr 2024-10-19T13:17:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-nicotine-inhaler-for-smoking-cessation-moves-to-trial-phase-kfyr 2024-10-19T13:17:29+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-presents-positive-results-from-the-ongoing-clinical-trial-of-its-btk 2024-10-19T12:28:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-presents-positive-results-from-the-ongoing-clinical-trial-of-its-btk 2024-10-19T12:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immune-checkpoint-inhibitor-therapy-improves-outcomes-in-early-breast-cancer 2024-10-19T11:59:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immune-checkpoint-inhibitor-therapy-improves-outcomes-in-early-breast-cancer 2024-10-19T11:59:41+00:00 weekly 0.7 https://trial.medpath.com/news/zakharia-evaluates-available-combination-options-for-non-clear-cell-rcc 2024-10-19T11:50:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zakharia-evaluates-available-combination-options-for-non-clear-cell-rcc 2024-10-19T11:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-treatment-for-regeneration-of-the-rotator-cuff-study-protocol-for-a-prospective-single 2024-10-19T11:50:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cell-treatment-for-regeneration-of-the-rotator-cuff-study-protocol-for-a-prospective-single 2024-10-19T11:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-the-british-biotech-disrupting-cancer-treatment-share-talk 2024-10-19T11:24:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avacta-the-british-biotech-disrupting-cancer-treatment-share-talk 2024-10-19T11:24:27+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-study-reports-similar-efficacy-between-sb17-stelara-in-psoriasis 2024-10-19T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-study-reports-similar-efficacy-between-sb17-stelara-in-psoriasis 2024-10-19T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatments-enhance-care-for-diverse-range-of-patients-with-psoriasis 2024-10-19T10:46:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatments-enhance-care-for-diverse-range-of-patients-with-psoriasis 2024-10-19T10:46:05+00:00 weekly 0.7 https://trial.medpath.com/news/common-cholesterol-drug-slows-mental-decline-from-alzheimer-s-disease 2024-10-19T10:41:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/common-cholesterol-drug-slows-mental-decline-from-alzheimer-s-disease 2024-10-19T10:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-reveals-elevated-triglyceride-levels-in-major-depressive-disorder-patients 2024-10-19T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-reveals-elevated-triglyceride-levels-in-major-depressive-disorder-patients 2024-10-19T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/three-year-results-for-eylea-hd-r-aflibercept-injection-8-globenewswire 2024-10-19T09:06:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-year-results-for-eylea-hd-r-aflibercept-injection-8-globenewswire 2024-10-19T09:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-io-io-data-contest-the-role-of-frontline-tkis-in-advanced-rcc-onclive 2024-10-19T08:09:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-io-io-data-contest-the-role-of-frontline-tkis-in-advanced-rcc-onclive 2024-10-19T08:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/integrated-cardio-renal-metabolic-care-models-face-implementation-challenges-despite-promise 2024-10-19T07:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/integrated-cardio-renal-metabolic-care-models-face-implementation-challenges-despite-promise 2024-10-19T07:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/no-link-found-between-prenatal-cannabis-use-and-early-childhood-disorders 2024-10-19T07:15:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-link-found-between-prenatal-cannabis-use-and-early-childhood-disorders 2024-10-19T07:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/wma-updates-declaration-of-helsinki-with-enhanced-focus-on-research-ethics-and-inclusion 2024-10-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wma-updates-declaration-of-helsinki-with-enhanced-focus-on-research-ethics-and-inclusion 2024-10-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be-cool-the-briefing-for-18-october-2024-global-competition-review 2024-10-19T04:54:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/be-cool-the-briefing-for-18-october-2024-global-competition-review 2024-10-19T04:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2a-of-cmtx-101-clinical-trial-for-cf-lung-infections-starts 2024-10-19T04:52:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2a-of-cmtx-101-clinical-trial-for-cf-lung-infections-starts 2024-10-19T04:52:06+00:00 weekly 0.7 https://trial.medpath.com/news/optimal-timing-for-video-assisted-thoracic-surgery-decortication-for-improved-survival-in 2024-10-19T04:18:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimal-timing-for-video-assisted-thoracic-surgery-decortication-for-improved-survival-in 2024-10-19T04:18:12+00:00 weekly 0.7 https://trial.medpath.com/news/managing-medication-overuse-headache-in-chronic-migraine-drug-topics 2024-10-19T04:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-medication-overuse-headache-in-chronic-migraine-drug-topics 2024-10-19T04:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/new-atezolizumab-formulation-for-subcutaneous-injection-research-aacr 2024-10-19T03:48:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-atezolizumab-formulation-for-subcutaneous-injection-research-aacr 2024-10-19T03:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-drug-tied-to-vision-loss-study-suggests-becker-s-hospital-review 2024-10-19T03:42:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-cancer-drug-tied-to-vision-loss-study-suggests-becker-s-hospital-review 2024-10-19T03:42:26+00:00 weekly 0.7 https://trial.medpath.com/news/tevogen-ceo-expresses-gratitude-for-unprecedented-public-globenewswire 2024-10-19T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tevogen-ceo-expresses-gratitude-for-unprecedented-public-globenewswire 2024-10-19T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/tranexamic-acid-for-reduction-of-intra-and-postoperative-transfusion-requirements-in-trials 2024-10-19T02:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tranexamic-acid-for-reduction-of-intra-and-postoperative-transfusion-requirements-in-trials 2024-10-19T02:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/international-medical-graduates-vital-to-addressing-u-s-oncology-workforce-shortage 2024-10-19T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/international-medical-graduates-vital-to-addressing-u-s-oncology-workforce-shortage 2024-10-19T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/supernus-depression-drug-improved-symptoms-in-two-hours-in-phase-iia-study 2024-10-19T00:29:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/supernus-depression-drug-improved-symptoms-in-two-hours-in-phase-iia-study 2024-10-19T00:29:04+00:00 weekly 0.7 https://trial.medpath.com/news/botox-r-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe 2024-10-19T00:13:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/botox-r-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe 2024-10-19T00:13:25+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-persistence-with-ocrelizumab-in-multiple-sclerosis-patients 2024-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-persistence-with-ocrelizumab-in-multiple-sclerosis-patients 2024-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bra-lliant-breakthrough-ultrasound-bra-detects-breast-cancer-at-home-wilx 2024-10-18T22:48:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bra-lliant-breakthrough-ultrasound-bra-detects-breast-cancer-at-home-wilx 2024-10-18T22:48:25+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-wins-fda-nods-for-nav-enabled-farapulse-catheter-software-massdevice 2024-10-18T22:28:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-wins-fda-nods-for-nav-enabled-farapulse-catheter-software-massdevice 2024-10-18T22:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-premature-aging-disease-treatment-mirage-news 2024-10-18T22:16:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-premature-aging-disease-treatment-mirage-news 2024-10-18T22:16:49+00:00 weekly 0.7 https://trial.medpath.com/news/tiziana-life-sciences-advances-with-promising-drug-trials-tipranks-com 2024-10-18T21:29:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiziana-life-sciences-advances-with-promising-drug-trials-tipranks-com 2024-10-18T21:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/ep-104iar-phase-2-data-shows-potential-for-knee-osteoarthritis-pain-hcplive 2024-10-18T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ep-104iar-phase-2-data-shows-potential-for-knee-osteoarthritis-pain-hcplive 2024-10-18T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/press-releases-friday-oct-18-2024-genentech 2024-10-18T21:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-releases-friday-oct-18-2024-genentech 2024-10-18T21:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-for-liver-cancer-shrinking-tumors-growing-responses 2024-10-18T20:59:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-for-liver-cancer-shrinking-tumors-growing-responses 2024-10-18T20:59:28+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-at-fda-new-guidances-address-cancer-pros-neurodevelopmental-safety 2024-10-18T20:42:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-at-fda-new-guidances-address-cancer-pros-neurodevelopmental-safety 2024-10-18T20:42:44+00:00 weekly 0.7 https://trial.medpath.com/news/selinexor-receives-approval-in-south-korea-for-multiple-myeloma-onclive 2024-10-18T19:55:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/selinexor-receives-approval-in-south-korea-for-multiple-myeloma-onclive 2024-10-18T19:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-october-18-2024 2024-10-18T19:07:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-october-18-2024 2024-10-18T19:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/successful-special-procedure-study-conduct-cerebrospinal-fluid-csf-and-concurrent 2024-10-18T19:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/successful-special-procedure-study-conduct-cerebrospinal-fluid-csf-and-concurrent 2024-10-18T19:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/partnering-for-precision-in-an-ipf-study-securing-timely-deliverables-and-key-endpoints 2024-10-18T19:07:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/partnering-for-precision-in-an-ipf-study-securing-timely-deliverables-and-key-endpoints 2024-10-18T19:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-back-decision-on-sotorasib-panitumumab-in-colorectal-cancer 2024-10-18T18:10:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pushes-back-decision-on-sotorasib-panitumumab-in-colorectal-cancer 2024-10-18T18:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/botensilimab-plus-balstilimab-elicits-durable-responses-in-refractory-metastatic-sarcoma 2024-10-18T18:09:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/botensilimab-plus-balstilimab-elicits-durable-responses-in-refractory-metastatic-sarcoma 2024-10-18T18:09:57+00:00 weekly 0.7 https://trial.medpath.com/news/eu-may-approve-oxford-astrazeneca-vaccine-this-week-says-german-health-ministry-spokesman 2024-10-18T17:53:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-may-approve-oxford-astrazeneca-vaccine-this-week-says-german-health-ministry-spokesman 2024-10-18T17:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/cognivue-clarity-characterizes-mild-cognitive-impairment-and-alzheimer-s-disease-in-nature 2024-10-18T17:39:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cognivue-clarity-characterizes-mild-cognitive-impairment-and-alzheimer-s-disease-in-nature 2024-10-18T17:39:31+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-18T17:20:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-18T17:20:22+00:00 weekly 0.7 https://trial.medpath.com/news/tme-pharma-reports-h1-2024-financial-results-and-provides-business-and-clinical-update 2024-10-18T16:44:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tme-pharma-reports-h1-2024-financial-results-and-provides-business-and-clinical-update 2024-10-18T16:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/autoantibodies-to-protein-s-may-explain-rare-cases-of-coagulopathy-following-covid-19-vaccination 2024-10-18T16:28:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autoantibodies-to-protein-s-may-explain-rare-cases-of-coagulopathy-following-covid-19-vaccination 2024-10-18T16:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/companies-to-watch-spinogenix-life-science-leader 2024-10-18T16:12:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/companies-to-watch-spinogenix-life-science-leader 2024-10-18T16:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/european-equities-close-mostly-higher-in-friday-trading-novo-nordisk-s-catalent-tradingview 2024-10-18T16:03:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-equities-close-mostly-higher-in-friday-trading-novo-nordisk-s-catalent-tradingview 2024-10-18T16:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-first-in-class-intracellular-checkpoint-inhibitor-of-dgk-and-z-stemming-from-phenotypic-screening 2024-10-18T15:48:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-first-in-class-intracellular-checkpoint-inhibitor-of-dgk-and-z-stemming-from-phenotypic-screening 2024-10-18T15:48:20+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-s-reign-over-the-drug-development-pipeline-continues-amcp-nexus-2024 2024-10-18T15:48:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-s-reign-over-the-drug-development-pipeline-continues-amcp-nexus-2024 2024-10-18T15:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/a-wechat-platform-program-wcpp-for-full-process-management-of-patients-with-cardiac-trials 2024-10-18T15:41:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-wechat-platform-program-wcpp-for-full-process-management-of-patients-with-cardiac-trials 2024-10-18T15:41:19+00:00 weekly 0.7 https://trial.medpath.com/news/time-to-sustained-recovery-among-outpatients-with-covid-19-receiving-montelukast-vs-placebo 2024-10-18T15:25:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/time-to-sustained-recovery-among-outpatients-with-covid-19-receiving-montelukast-vs-placebo 2024-10-18T15:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-several-medicines-in-october-biopharm-international 2024-10-18T15:24:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-recommends-several-medicines-in-october-biopharm-international 2024-10-18T15:24:19+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-rebuffed-again-by-ema-novartis-licenses-china-based-biotech-s-cancer-drug 2024-10-18T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-rebuffed-again-by-ema-novartis-licenses-china-based-biotech-s-cancer-drug 2024-10-18T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-bioresearch-monitoring-technical-specifications-document-to-help-you 2024-10-18T15:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-bioresearch-monitoring-technical-specifications-document-to-help-you 2024-10-18T15:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-francis-crick-institute-launches-a-new-project-aimed-at-understanding-immunotherapy-vwv 2024-10-18T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-francis-crick-institute-launches-a-new-project-aimed-at-understanding-immunotherapy-vwv 2024-10-18T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/news/ucla-study-aims-to-develop-same-day-detection-of-cancer-cells-in-cerebrospinal-fluid 2024-10-18T14:56:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucla-study-aims-to-develop-same-day-detection-of-cancer-cells-in-cerebrospinal-fluid 2024-10-18T14:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/inotuzumab-ozogamicin-in-pediatric-patients-with-relapsed-or-refractory-b-cell-all 2024-10-18T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inotuzumab-ozogamicin-in-pediatric-patients-with-relapsed-or-refractory-b-cell-all 2024-10-18T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/endo-presents-data-at-the-american-society-of-podiatric-surgeons-asps-annual-surgical 2024-10-18T14:37:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endo-presents-data-at-the-american-society-of-podiatric-surgeons-asps-annual-surgical 2024-10-18T14:37:10+00:00 weekly 0.7 https://trial.medpath.com/news/repurposed-als-drug-shows-promise-against-aggressive-brain-tumors 2024-10-18T14:32:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repurposed-als-drug-shows-promise-against-aggressive-brain-tumors 2024-10-18T14:32:09+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-designations-may-jumpstart-gene-therapy-development 2024-10-18T14:22:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fda-designations-may-jumpstart-gene-therapy-development 2024-10-18T14:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-anovo-system-for-abdominal-hernia-repair-the-jerusalem-post 2024-10-18T14:02:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-anovo-system-for-abdominal-hernia-repair-the-jerusalem-post 2024-10-18T14:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/ema-awards-prime-status-to-pentixapharm-s-ga68-pentixafor-webdisclosure 2024-10-18T14:02:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-awards-prime-status-to-pentixapharm-s-ga68-pentixafor-webdisclosure 2024-10-18T14:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-trial-results-of-novel-triple-combination-pill-for-hypertension-published-in-the-lancet 2024-10-18T13:46:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-trial-results-of-novel-triple-combination-pill-for-hypertension-published-in-the-lancet 2024-10-18T13:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-to-present-data-at-the-2024-annual-scientific-meeting-of-the-biospace 2024-10-18T13:46:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-pharmaceuticals-to-present-data-at-the-2024-annual-scientific-meeting-of-the-biospace 2024-10-18T13:46:05+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-biopharma-ltd-american-depositary-shares-each-representing-three-hundred 2024-10-18T13:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-biopharma-ltd-american-depositary-shares-each-representing-three-hundred 2024-10-18T13:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/brown-glaberman-reviews-data-for-pik3ca-altered-metastatic-breast-cancer 2024-10-18T13:38:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brown-glaberman-reviews-data-for-pik3ca-altered-metastatic-breast-cancer 2024-10-18T13:38:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-back-pdufa-dates-for-amgen-and-intercept-biospace 2024-10-18T13:26:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pushes-back-pdufa-dates-for-amgen-and-intercept-biospace 2024-10-18T13:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/significant-positive-results-from-osteoarthritis-clinical-study-in-dogs-treated-with-piclidenoson 2024-10-18T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/significant-positive-results-from-osteoarthritis-clinical-study-in-dogs-treated-with-piclidenoson 2024-10-18T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-livionex-reports-positive-end-of-phase-2-meeting-with-fda-on-the-development 2024-10-18T13:07:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-livionex-reports-positive-end-of-phase-2-meeting-with-fda-on-the-development 2024-10-18T13:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/cerus-corporation-announces-workshop-and-abstracts-at-the-2024-aabb-annual-meeting 2024-10-18T12:50:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerus-corporation-announces-workshop-and-abstracts-at-the-2024-aabb-annual-meeting 2024-10-18T12:50:44+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-announces-that-enrollment-in-its-adult-acute-kidney-injury-pivotal-trial-has 2024-10-18T12:47:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seastar-medical-announces-that-enrollment-in-its-adult-acute-kidney-injury-pivotal-trial-has 2024-10-18T12:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-provides-update-on-u-s-indication-for-trodelvy-r-in-metastatic-urothelial-cancer 2024-10-18T12:39:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-provides-update-on-u-s-indication-for-trodelvy-r-in-metastatic-urothelial-cancer 2024-10-18T12:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/msd-mulls-2025-26-launch-for-rsv-vaccine-after-phase-ii-iii-win 2024-10-18T12:27:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msd-mulls-2025-26-launch-for-rsv-vaccine-after-phase-ii-iii-win 2024-10-18T12:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/safety-data-help-affirm-adjuvant-alectinib-as-a-new-soc-in-alk-nsclc-onclive 2024-10-18T12:20:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-data-help-affirm-adjuvant-alectinib-as-a-new-soc-in-alk-nsclc-onclive 2024-10-18T12:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-s-amx0035-shows-promise-in-phase-ii-wolfram-syndrome-trial 2024-10-18T11:19:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amylyx-s-amx0035-shows-promise-in-phase-ii-wolfram-syndrome-trial 2024-10-18T11:19:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-declares-iv-fluid-shortage-following-hurricane-impact-on-baxter-facilities 2024-10-18T11:12:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-declares-iv-fluid-shortage-following-hurricane-impact-on-baxter-facilities 2024-10-18T11:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/lanova-medicines-announces-initiation-of-phase-1-clinical-trial-of-anti-pd-1-vegf-biospace 2024-10-18T11:01:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lanova-medicines-announces-initiation-of-phase-1-clinical-trial-of-anti-pd-1-vegf-biospace 2024-10-18T11:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-bel-sar-shows-promising-safety-efficacy-in-nmibc-in-phase-1-study 2024-10-18T10:20:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-dose-bel-sar-shows-promising-safety-efficacy-in-nmibc-in-phase-1-study 2024-10-18T10:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-confirms-rsv-vaccine-s-protective-power-for-seniors 2024-10-18T10:06:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-confirms-rsv-vaccine-s-protective-power-for-seniors 2024-10-18T10:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/evergreen-theragnostics-opens-cck2-view-a-phase-ii-small-cell-lung-cancer-clinical-trial 2024-10-18T10:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evergreen-theragnostics-opens-cck2-view-a-phase-ii-small-cell-lung-cancer-clinical-trial 2024-10-18T10:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/translarna-ema-re-confirms-non-renewal-of-authorisation-of-duchenne-muscular-dystrophy 2024-10-18T10:01:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/translarna-ema-re-confirms-non-renewal-of-authorisation-of-duchenne-muscular-dystrophy 2024-10-18T10:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-approval-of-novo-nordisk-hemophilia-drug-medwatch 2024-10-18T09:57:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-approval-of-novo-nordisk-hemophilia-drug-medwatch 2024-10-18T09:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/response-begins-enrolment-for-trial-of-rdx-002-for-weight-management 2024-10-18T09:47:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/response-begins-enrolment-for-trial-of-rdx-002-for-weight-management 2024-10-18T09:47:33+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-a-s-alhemo-r-recommended-for-european-approval-globenewswire 2024-10-18T09:38:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-a-s-alhemo-r-recommended-for-european-approval-globenewswire 2024-10-18T09:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/risk-stratification-and-population-health-key-to-revolutionizing-ckd-care-management 2024-10-18T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-stratification-and-population-health-key-to-revolutionizing-ckd-care-management 2024-10-18T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-phase-clinical-trials-for-the-development-of-novel-immunotherapeutic-anti-cancer-agents 2024-10-18T08:31:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-phase-clinical-trials-for-the-development-of-novel-immunotherapeutic-anti-cancer-agents 2024-10-18T08:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/social-determinants-create-stark-disparities-in-type-2-diabetes-care-and-outcomes 2024-10-18T08:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/social-determinants-create-stark-disparities-in-type-2-diabetes-care-and-outcomes 2024-10-18T08:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-us-225-million-investment-towards-world-class-research-institute 2024-10-18T07:51:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-weekly-us-225-million-investment-towards-world-class-research-institute 2024-10-18T07:51:38+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-unmc-research-studies-abc-s-of-icu-care-newsroom 2024-10-18T07:11:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/landmark-unmc-research-studies-abc-s-of-icu-care-newsroom 2024-10-18T07:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/nitrogen-dioxide-air-pollution-linked-to-21-higher-ovarian-cancer-risk-in-us-study 2024-10-18T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nitrogen-dioxide-air-pollution-linked-to-21-higher-ovarian-cancer-risk-in-us-study 2024-10-18T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vaccine-against-the-mers-coronavirus-tested-as-safe-and-effective-in-phase-ib-clinical-trial 2024-10-18T06:59:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaccine-against-the-mers-coronavirus-tested-as-safe-and-effective-in-phase-ib-clinical-trial 2024-10-18T06:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-biomedical-steriwave-receives-uae-regulatory-approval-research-tree 2024-10-18T06:17:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ondine-biomedical-steriwave-receives-uae-regulatory-approval-research-tree 2024-10-18T06:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-clinical-trials-receive-22m-funding-boost-hospital-healthcare 2024-10-18T05:49:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-clinical-trials-receive-22m-funding-boost-hospital-healthcare 2024-10-18T05:49:28+00:00 weekly 0.7 https://trial.medpath.com/news/machine-learning-based-model-for-cd4-conventional-t-cell-genes-to-predict-survival-and 2024-10-18T05:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/machine-learning-based-model-for-cd4-conventional-t-cell-genes-to-predict-survival-and 2024-10-18T05:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-of-psma-pet-ct-versus-planar-bone-scan-and-ct-in-prostate-cancer-patients-nature 2024-10-18T03:56:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-trial-of-psma-pet-ct-versus-planar-bone-scan-and-ct-in-prostate-cancer-patients-nature 2024-10-18T03:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/comparing-remimazolam-and-propofol-for-postoperative-anesthesia-satisf-dddt 2024-10-18T03:54:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparing-remimazolam-and-propofol-for-postoperative-anesthesia-satisf-dddt 2024-10-18T03:54:37+00:00 weekly 0.7 https://trial.medpath.com/news/inhalerx-procures-38-5m-in-funding-from-clendon-biotech-to-progress-inhaled-therapies 2024-10-18T03:25:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inhalerx-procures-38-5m-in-funding-from-clendon-biotech-to-progress-inhaled-therapies 2024-10-18T03:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-ezetimib-rifampin-may-increase-coproporphyrin-concentrations-in-healthy-patients 2024-10-18T01:24:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-ezetimib-rifampin-may-increase-coproporphyrin-concentrations-in-healthy-patients 2024-10-18T01:24:48+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-announces-plans-to-voluntarily-withdraw-the-u-s-accelerated-approval-for-trodelvy-in-metastatic-urothelial-cancer 2024-10-18T01:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-announces-plans-to-voluntarily-withdraw-the-u-s-accelerated-approval-for-trodelvy-in-metastatic-urothelial-cancer 2024-10-18T01:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/promising-growth-and-innovation-drive-buy-recommendation-for-rapport-therapeutics-inc 2024-10-18T00:36:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-growth-and-innovation-drive-buy-recommendation-for-rapport-therapeutics-inc 2024-10-18T00:36:20+00:00 weekly 0.7 https://trial.medpath.com/news/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe-vertical-bands-connecting-the-jaw-and-neck-platysma-bands 2024-10-18T00:10:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe-vertical-bands-connecting-the-jaw-and-neck-platysma-bands 2024-10-18T00:10:37+00:00 weekly 0.7 https://trial.medpath.com/news/unlearn-s-digital-twins-slash-pharma-trial-costs-by-millions-drug-discovery-and-development 2024-10-17T23:31:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unlearn-s-digital-twins-slash-pharma-trial-costs-by-millions-drug-discovery-and-development 2024-10-17T23:31:04+00:00 weekly 0.7 https://trial.medpath.com/news/nih-awards-acri-2-9-million-for-critical-cystic-fibrosis-therapy-research 2024-10-17T22:40:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-awards-acri-2-9-million-for-critical-cystic-fibrosis-therapy-research 2024-10-17T22:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv 2024-10-17T22:25:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv 2024-10-17T22:25:21+00:00 weekly 0.7 https://trial.medpath.com/news/tryptamine-therapeutics-advances-psilocin-drug-trials-tipranks-com 2024-10-17T22:20:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tryptamine-therapeutics-advances-psilocin-drug-trials-tipranks-com 2024-10-17T22:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-sells-viatris-rights-to-cardio-drug-outside-of-the-u-s-and-europe-biopharma-dive 2024-10-17T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-sells-viatris-rights-to-cardio-drug-outside-of-the-u-s-and-europe-biopharma-dive 2024-10-17T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/dr-nowakowski-on-the-implications-of-the-fda-approval-of-epcoritamab-in-follicular-lymphoma 2024-10-17T20:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-nowakowski-on-the-implications-of-the-fda-approval-of-epcoritamab-in-follicular-lymphoma 2024-10-17T20:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/cabozantinib-plus-atezolizumab-fails-to-improve-os-over-subsequent-novel-hormonal 2024-10-17T20:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabozantinib-plus-atezolizumab-fails-to-improve-os-over-subsequent-novel-hormonal 2024-10-17T20:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-insights-denileukin-diftitox-in-relapsed-refractory-ctcl-onclive 2024-10-17T20:08:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-insights-denileukin-diftitox-in-relapsed-refractory-ctcl-onclive 2024-10-17T20:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/sage-lays-off-55-of-r-d-workforce-and-refocuses-pipeline-yahoo-finance 2024-10-17T19:58:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-lays-off-55-of-r-d-workforce-and-refocuses-pipeline-yahoo-finance 2024-10-17T19:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/intercept-s-liver-disease-drug-faces-full-approval-delay-following-negative-adcomm 2024-10-17T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intercept-s-liver-disease-drug-faces-full-approval-delay-following-negative-adcomm 2024-10-17T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/news/the-positive-choices-trial-update-to-study-protocol-for-a-phase-iii-rct-trial-of-a-whole-trials 2024-10-17T19:12:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-positive-choices-trial-update-to-study-protocol-for-a-phase-iii-rct-trial-of-a-whole-trials 2024-10-17T19:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/3-takeaways-from-bcrf-s-webinar-on-metastatic-breast-cancer 2024-10-17T19:06:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-takeaways-from-bcrf-s-webinar-on-metastatic-breast-cancer 2024-10-17T19:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/mcgregor-and-participants-discuss-impact-of-drug-efficacy-and-histology-on-nccrcc-care 2024-10-17T19:02:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mcgregor-and-participants-discuss-impact-of-drug-efficacy-and-histology-on-nccrcc-care 2024-10-17T19:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/conditional-fda-approval-pathway-bill-introduced-in-house-insidehealthpolicy-com 2024-10-17T18:37:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/conditional-fda-approval-pathway-bill-introduced-in-house-insidehealthpolicy-com 2024-10-17T18:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/ab-science-faces-setback-in-ema-approval-for-als-treatment-webdisclosure 2024-10-17T18:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ab-science-faces-setback-in-ema-approval-for-als-treatment-webdisclosure 2024-10-17T18:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/buprenorphine-naloxone-vs-methadone-for-the-treatment-of-opioid-use-disorder 2024-10-17T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buprenorphine-naloxone-vs-methadone-for-the-treatment-of-opioid-use-disorder 2024-10-17T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/early-drug-treatment-in-preterm-patients-with-large-patent-ductus-arteriosus-at-28-weeks-or 2024-10-17T18:29:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-drug-treatment-in-preterm-patients-with-large-patent-ductus-arteriosus-at-28-weeks-or 2024-10-17T18:29:18+00:00 weekly 0.7 https://trial.medpath.com/news/more-companies-share-upcoming-aao-presentation-information-modern-retina 2024-10-17T18:15:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-companies-share-upcoming-aao-presentation-information-modern-retina 2024-10-17T18:15:20+00:00 weekly 0.7 https://trial.medpath.com/news/speakers-highlight-2024-regulatory-moves-in-hypertension-lipid-diabetes-therapies-healio 2024-10-17T17:51:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/speakers-highlight-2024-regulatory-moves-in-hypertension-lipid-diabetes-therapies-healio 2024-10-17T17:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-study-on-conversion-therapy-of-hepatocellular-carcinoma-bmc-gastroenterology 2024-10-17T17:48:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-study-on-conversion-therapy-of-hepatocellular-carcinoma-bmc-gastroenterology 2024-10-17T17:48:06+00:00 weekly 0.7 https://trial.medpath.com/news/estimating-the-true-prevalence-of-mash-and-masld-in-the-us 2024-10-17T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/estimating-the-true-prevalence-of-mash-and-masld-in-the-us 2024-10-17T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-treating-neurological-diseases-mirage-news 2024-10-17T16:36:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-treating-neurological-diseases-mirage-news 2024-10-17T16:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-thoracic-radiotherapy-to-first-line-treatment-of-egfr-mutated-metastatic-nsclc 2024-10-17T16:24:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-thoracic-radiotherapy-to-first-line-treatment-of-egfr-mutated-metastatic-nsclc 2024-10-17T16:24:15+00:00 weekly 0.7 https://trial.medpath.com/news/tafasitamab-plus-lenalidomide-wins-approval-in-mexico-for-asct-ineligible-r-r-dlbcl 2024-10-17T16:22:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tafasitamab-plus-lenalidomide-wins-approval-in-mexico-for-asct-ineligible-r-r-dlbcl 2024-10-17T16:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/custom-alterations-mending-genes-for-long-lasting-effects-newswise 2024-10-17T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/custom-alterations-mending-genes-for-long-lasting-effects-newswise 2024-10-17T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/for-fred-hutch-biostatisticians-numbers-are-no-game-fred-hutchinson-cancer-center 2024-10-17T16:04:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/for-fred-hutch-biostatisticians-numbers-are-no-game-fred-hutchinson-cancer-center 2024-10-17T16:04:31+00:00 weekly 0.7 https://trial.medpath.com/news/new-biomarker-predicts-immunotherapy-response-in-hepatocellular-carcinoma 2024-10-17T15:49:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-biomarker-predicts-immunotherapy-response-in-hepatocellular-carcinoma 2024-10-17T15:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/four-people-died-after-receiving-the-russian-sputnik-v-vaccine-telegrafi 2024-10-17T15:37:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-people-died-after-receiving-the-russian-sputnik-v-vaccine-telegrafi 2024-10-17T15:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/yourgene-health-cystic-fibrosis-base-assay-receives-ivdr-accreditation 2024-10-17T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yourgene-health-cystic-fibrosis-base-assay-receives-ivdr-accreditation 2024-10-17T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/can-avutometinib-win-the-title-of-first-breakthrough-treatment-for-recurrent-kras-rttnews 2024-10-17T14:33:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-avutometinib-win-the-title-of-first-breakthrough-treatment-for-recurrent-kras-rttnews 2024-10-17T14:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/bioaegis-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-of-gelsolin-an-immune 2024-10-17T14:29:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioaegis-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-of-gelsolin-an-immune 2024-10-17T14:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing 2024-10-17T14:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing 2024-10-17T14:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/biostem-technologies-reports-breakthrough-results-in-a-diabetic-foot-ulcer-wound-biospace 2024-10-17T14:28:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biostem-technologies-reports-breakthrough-results-in-a-diabetic-foot-ulcer-wound-biospace 2024-10-17T14:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/october-17-2024-ggc4h-pilot-finds-spanish-language-intervention-feasible-and 2024-10-17T14:17:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-17-2024-ggc4h-pilot-finds-spanish-language-intervention-feasible-and 2024-10-17T14:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/harmonized-data-quality-indicators-maintain-data-quality-in-long-term-clep 2024-10-17T14:00:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harmonized-data-quality-indicators-maintain-data-quality-in-long-term-clep 2024-10-17T14:00:17+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-focused-digital-health-startup-closes-after-an-fda-rejection-stat-news 2024-10-17T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-focused-digital-health-startup-closes-after-an-fda-rejection-stat-news 2024-10-17T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-foscarbidopa-foslevodopa-for-motor-fluctuations-in-adults-with-parkinson-disease 2024-10-17T13:53:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-foscarbidopa-foslevodopa-for-motor-fluctuations-in-adults-with-parkinson-disease 2024-10-17T13:53:55+00:00 weekly 0.7 https://trial.medpath.com/news/in-a-breakthrough-indian-scientists-develop-unique-method-to-treat-brain-tuberculosis 2024-10-17T13:53:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-a-breakthrough-indian-scientists-develop-unique-method-to-treat-brain-tuberculosis 2024-10-17T13:53:40+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-t-cell-response-and-safety-of-a-tetravalent-dengue-vaccine-in-healthy-children 2024-10-17T13:48:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-t-cell-response-and-safety-of-a-tetravalent-dengue-vaccine-in-healthy-children 2024-10-17T13:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/avadel-pharmaceuticals-announces-fda-approval-of-lumryztm-sodium-oxybate 2024-10-17T13:46:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avadel-pharmaceuticals-announces-fda-approval-of-lumryztm-sodium-oxybate 2024-10-17T13:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-extends-review-of-obeticholic-acid-ocaliva-snda-for-primary-biliary-cholangitis 2024-10-17T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-extends-review-of-obeticholic-acid-ocaliva-snda-for-primary-biliary-cholangitis 2024-10-17T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/bms-opdivo-bests-pfizer-s-adcetris-in-late-stage-hodgkin-s-lymphoma-study-biospace 2024-10-17T13:19:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-opdivo-bests-pfizer-s-adcetris-in-late-stage-hodgkin-s-lymphoma-study-biospace 2024-10-17T13:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/more-evidence-on-glp-1s-and-opioid-addiction-stat-news 2024-10-17T13:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-evidence-on-glp-1s-and-opioid-addiction-stat-news 2024-10-17T13:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/preparing-for-responsive-management-versus-preparing-for-renal-dialysis-in-multimorbid-trials 2024-10-17T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preparing-for-responsive-management-versus-preparing-for-renal-dialysis-in-multimorbid-trials 2024-10-17T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-announces-data-presentations-at-the-american-the-manila-times 2024-10-17T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-announces-data-presentations-at-the-american-the-manila-times 2024-10-17T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-can-approve-cheaper-copycat-of-heart-failure-drug-entresto-judge-says 2024-10-17T12:57:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-can-approve-cheaper-copycat-of-heart-failure-drug-entresto-judge-says 2024-10-17T12:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-quantisnow 2024-10-17T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-quantisnow 2024-10-17T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/zanubrutinib-shows-limited-cost-effectiveness-against-r-bendamustine-for-first-line-cll-treatment-in-china 2024-10-17T12:47:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zanubrutinib-shows-limited-cost-effectiveness-against-r-bendamustine-for-first-line-cll-treatment-in-china 2024-10-17T12:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-announces-rave-lite-to-support-growth-in-early-and-late-stage-clinical-trials 2024-10-17T12:35:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-announces-rave-lite-to-support-growth-in-early-and-late-stage-clinical-trials 2024-10-17T12:35:16+00:00 weekly 0.7 https://trial.medpath.com/news/igc-pharma-announces-patient-enrollment-at-toronto-s-baycrest-in-phase-2-trial 2024-10-17T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/igc-pharma-announces-patient-enrollment-at-toronto-s-baycrest-in-phase-2-trial 2024-10-17T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-receives-mhra-approval-for-wainzua-in-rare-nerve-disease-attrv-pn 2024-10-17T12:23:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-receives-mhra-approval-for-wainzua-in-rare-nerve-disease-attrv-pn 2024-10-17T12:23:36+00:00 weekly 0.7 https://trial.medpath.com/news/diet-may-improve-brain-health-in-older-adults-with-obesity-national-institute-on-aging 2024-10-17T12:12:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diet-may-improve-brain-health-in-older-adults-with-obesity-national-institute-on-aging 2024-10-17T12:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/more-than-100-women-with-advanced-cancer-have-already-participated-in-the-impact-cnio 2024-10-17T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-than-100-women-with-advanced-cancer-have-already-participated-in-the-impact-cnio 2024-10-17T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/teva-and-mabxience-add-additional-oncology-biosimilar-candidate-expanding-strategic 2024-10-17T11:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-and-mabxience-add-additional-oncology-biosimilar-candidate-expanding-strategic 2024-10-17T11:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/melanoma-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-10-17T11:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melanoma-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-10-17T11:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/minor-cannabinoid-shows-promise-in-reducing-anxiety-drug-discovery-news 2024-10-17T11:26:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minor-cannabinoid-shows-promise-in-reducing-anxiety-drug-discovery-news 2024-10-17T11:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharmaceuticals-presents-clinical-data-from-pivotal-phase-3-raise-trial-in-morningstar 2024-10-17T11:08:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marinus-pharmaceuticals-presents-clinical-data-from-pivotal-phase-3-raise-trial-in-morningstar 2024-10-17T11:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/rozanolixizumab-efficacious-in-older-patients-with-generalized-myasthenia-gravis-phase 2024-10-17T10:12:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rozanolixizumab-efficacious-in-older-patients-with-generalized-myasthenia-gravis-phase 2024-10-17T10:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/kind-announces-late-breaking-abstract-accepted-for-presentation-on-and017-clinical 2024-10-17T10:10:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kind-announces-late-breaking-abstract-accepted-for-presentation-on-and017-clinical 2024-10-17T10:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/dad-s-use-of-diabetes-med-metformin-won-t-raise-birth-defect-risk 2024-10-17T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dad-s-use-of-diabetes-med-metformin-won-t-raise-birth-defect-risk 2024-10-17T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/concern-over-tga-rejection-of-alzheimer-s-drug-abc-listen 2024-10-17T09:32:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/concern-over-tga-rejection-of-alzheimer-s-drug-abc-listen 2024-10-17T09:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/for-multiple-sclerosis-medication-and-cognitive-behavioral-therapy-can-reduce-fatigue 2024-10-17T09:13:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/for-multiple-sclerosis-medication-and-cognitive-behavioral-therapy-can-reduce-fatigue 2024-10-17T09:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/australia-joins-eu-in-turning-down-alzheimer-s-drug-leqembi-pharmaphorum 2024-10-17T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/australia-joins-eu-in-turning-down-alzheimer-s-drug-leqembi-pharmaphorum 2024-10-17T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/latigo-biotherapeutics-doses-first-participant-in-phase-1-clinical-trial-of-ltg-305-for-non 2024-10-17T08:53:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/latigo-biotherapeutics-doses-first-participant-in-phase-1-clinical-trial-of-ltg-305-for-non 2024-10-17T08:53:15+00:00 weekly 0.7 https://trial.medpath.com/news/7th-annual-oct-dach-conference-to-address-clinical-trial-innovation-investment-and-diversity-challenges 2024-10-17T07:28:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/7th-annual-oct-dach-conference-to-address-clinical-trial-innovation-investment-and-diversity-challenges 2024-10-17T07:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-analysis-of-single-versus-tandem-autologous-stem-cell-transplantation-in-nature 2024-10-17T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-analysis-of-single-versus-tandem-autologous-stem-cell-transplantation-in-nature 2024-10-17T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-announces-health-canada-approval-of-daybuetm-trofinetide-for 2024-10-17T06:39:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-announces-health-canada-approval-of-daybuetm-trofinetide-for 2024-10-17T06:39:31+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharm-ventures-to-produce-radioantibody-for-atomvie-bioprocess-international 2024-10-17T06:28:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiopharm-ventures-to-produce-radioantibody-for-atomvie-bioprocess-international 2024-10-17T06:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/specialty-drug-coverage-disparities-create-access-barriers-as-pbms-push-for-benefit-integration 2024-10-17T05:43:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/specialty-drug-coverage-disparities-create-access-barriers-as-pbms-push-for-benefit-integration 2024-10-17T05:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-antibiotic-shows-efficacy-safety-in-late-stage-trial-for-uncomplicated-gonorrhea 2024-10-17T05:28:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-antibiotic-shows-efficacy-safety-in-late-stage-trial-for-uncomplicated-gonorrhea 2024-10-17T05:28:39+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-hiv-vaccine-to-induce-virus-specific-neutralizing-antibodies 2024-10-17T05:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-hiv-vaccine-to-induce-virus-specific-neutralizing-antibodies 2024-10-17T05:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/loncastuximab-tesirine-demonstrates-promise-in-managing-hemophagocytic-pharmacy-times 2024-10-17T04:07:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/loncastuximab-tesirine-demonstrates-promise-in-managing-hemophagocytic-pharmacy-times 2024-10-17T04:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-clinical-trial-testing-digital-mindset-intervention-for-knee-osteoarthritis-pain-and 2024-10-17T02:23:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-clinical-trial-testing-digital-mindset-intervention-for-knee-osteoarthritis-pain-and 2024-10-17T02:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/gene-editing-approach-helps-launch-first-in-human-clinical-trial-for-rare-genetic-disease 2024-10-17T01:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-editing-approach-helps-launch-first-in-human-clinical-trial-for-rare-genetic-disease 2024-10-17T01:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/ai-support-significantly-improves-her2-scoring-accuracy-in-breast-cancer-diagnosis 2024-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-support-significantly-improves-her2-scoring-accuracy-in-breast-cancer-diagnosis 2024-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glaukos-reports-positive-phase-3-results-for-epioxa-ophthalmology-times 2024-10-16T23:50:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glaukos-reports-positive-phase-3-results-for-epioxa-ophthalmology-times 2024-10-16T23:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/hivma-honors-outstanding-achievements-in-hiv-clinical-education-and-research-with-idsa 2024-10-16T23:04:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hivma-honors-outstanding-achievements-in-hiv-clinical-education-and-research-with-idsa 2024-10-16T23:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-boosts-survival-of-advanced-hodgkin-lymphoma-in-clinical-trial 2024-10-16T21:14:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-boosts-survival-of-advanced-hodgkin-lymphoma-in-clinical-trial 2024-10-16T21:14:53+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-transplants-safe-when-donor-recipient-both-hiv-positive 2024-10-16T21:00:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-transplants-safe-when-donor-recipient-both-hiv-positive 2024-10-16T21:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-expands-its-board-of-directors-with-the-addition-of-drug-stock-titan 2024-10-16T20:58:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-expands-its-board-of-directors-with-the-addition-of-drug-stock-titan 2024-10-16T20:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 2024-10-16T20:18:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 2024-10-16T20:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/study-breast-cancer-drug-shows-potential-for-rare-appendix-cancer 2024-10-16T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-breast-cancer-drug-shows-potential-for-rare-appendix-cancer 2024-10-16T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-trims-neuroscience-pipeline-seltorexant-in-alzheimer-s-disease-dropped 2024-10-16T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-trims-neuroscience-pipeline-seltorexant-in-alzheimer-s-disease-dropped 2024-10-16T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/atlas-examines-tolerability-of-hedgehog-pathway-inhibitors-and-transition-to-io-in-mbcc 2024-10-16T19:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atlas-examines-tolerability-of-hedgehog-pathway-inhibitors-and-transition-to-io-in-mbcc 2024-10-16T19:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/bionj-medidata-tackle-underrepresentation-in-clinical-trials-njbiz 2024-10-16T18:47:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bionj-medidata-tackle-underrepresentation-in-clinical-trials-njbiz 2024-10-16T18:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-cleared-medical-devices-lack-proper-vetting-doctors-say-webmd 2024-10-16T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-cleared-medical-devices-lack-proper-vetting-doctors-say-webmd 2024-10-16T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/rna-editing-stocks-soar-on-wave-life-s-breakthrough-trial-data-yahoo-finance 2024-10-16T17:45:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rna-editing-stocks-soar-on-wave-life-s-breakthrough-trial-data-yahoo-finance 2024-10-16T17:45:26+00:00 weekly 0.7 https://trial.medpath.com/news/eximia-research-network-expands-into-iowa-with-acquisition-of-integrated-clinical-trial 2024-10-16T16:47:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eximia-research-network-expands-into-iowa-with-acquisition-of-integrated-clinical-trial 2024-10-16T16:47:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-puts-novavax-flu-vaccine-trials-on-hold-biopharma-dive 2024-10-16T16:20:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-puts-novavax-flu-vaccine-trials-on-hold-biopharma-dive 2024-10-16T16:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-ramucirumab-to-osimertinib-in-tki-naive-egfr-mutant-metastatic-nsclc 2024-10-16T16:04:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-ramucirumab-to-osimertinib-in-tki-naive-egfr-mutant-metastatic-nsclc 2024-10-16T16:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/osimertinib-plus-savolitinib-generates-durable-responses-in-egfr-mutant-met-amplified-nsclc 2024-10-16T15:57:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/osimertinib-plus-savolitinib-generates-durable-responses-in-egfr-mutant-met-amplified-nsclc 2024-10-16T15:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella 2024-10-16T15:54:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella 2024-10-16T15:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/bridget-koontz-md-on-the-rationale-for-the-phase-2-nrg-gu011-trial-urology-times 2024-10-16T15:43:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridget-koontz-md-on-the-rationale-for-the-phase-2-nrg-gu011-trial-urology-times 2024-10-16T15:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/synedgen-partners-with-barda-for-miist305-development-pharmaceutical-technology 2024-10-16T15:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synedgen-partners-with-barda-for-miist305-development-pharmaceutical-technology 2024-10-16T15:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-reveals-rna-editing-breakthrough-reports-first-ever-clinical-proof-of 2024-10-16T15:23:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wave-life-sciences-reveals-rna-editing-breakthrough-reports-first-ever-clinical-proof-of 2024-10-16T15:23:43+00:00 weekly 0.7 https://trial.medpath.com/news/bacterial-vaccine-shows-promise-as-cancer-immunotherapy-eurekalert 2024-10-16T15:16:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bacterial-vaccine-shows-promise-as-cancer-immunotherapy-eurekalert 2024-10-16T15:16:36+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-promising-outlook-with-ntla-2002-s-impressive-phase-ii-results-and 2024-10-16T15:07:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-therapeutics-promising-outlook-with-ntla-2002-s-impressive-phase-ii-results-and 2024-10-16T15:07:44+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-technology-leads-to-life-saving-treatment-for-deadly-skin-reaction 2024-10-16T15:05:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-technology-leads-to-life-saving-treatment-for-deadly-skin-reaction 2024-10-16T15:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/opinion-addition-of-olanzapine-is-effectively-manages-nausea-during-t-dxd-treatment 2024-10-16T15:02:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opinion-addition-of-olanzapine-is-effectively-manages-nausea-during-t-dxd-treatment 2024-10-16T15:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/results-of-phase-i-trial-shed-positive-light-on-uni-494-for-acute-kidney-injury 2024-10-16T14:51:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/results-of-phase-i-trial-shed-positive-light-on-uni-494-for-acute-kidney-injury 2024-10-16T14:51:34+00:00 weekly 0.7 https://trial.medpath.com/news/obsidian-solutions-group-secures-direct-to-phase-ii-award-from-afwerx-to-enhance 2024-10-16T14:48:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obsidian-solutions-group-secures-direct-to-phase-ii-award-from-afwerx-to-enhance 2024-10-16T14:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/us-advisory-committees-pink-sheet-citeline 2024-10-16T14:28:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-advisory-committees-pink-sheet-citeline 2024-10-16T14:28:47+00:00 weekly 0.7 https://trial.medpath.com/news/okyo-pharma-begins-phase-2-trial-for-ncp-treatment-investing-com 2024-10-16T14:25:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/okyo-pharma-begins-phase-2-trial-for-ncp-treatment-investing-com 2024-10-16T14:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-for-alcon-based-on-potential-fda-approval-of-ar-15512-despite-mixed-phase-3-results 2024-10-16T14:19:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-for-alcon-based-on-potential-fda-approval-of-ar-15512-despite-mixed-phase-3-results 2024-10-16T14:19:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-reporting-is-on-the-rise-nature 2024-10-16T14:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-reporting-is-on-the-rise-nature 2024-10-16T14:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-bio-announces-fda-clearance-of-ind-amendment-to-evaluate-adi-001-in-markets-data 2024-10-16T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adicet-bio-announces-fda-clearance-of-ind-amendment-to-evaluate-adi-001-in-markets-data 2024-10-16T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-in-europe-dosed-in-the-clinical-phase-2b-pointer-study-placera 2024-10-16T13:34:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-in-europe-dosed-in-the-clinical-phase-2b-pointer-study-placera 2024-10-16T13:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/a-controversial-approval-for-novocure-s-device-stat-news 2024-10-16T13:18:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-controversial-approval-for-novocure-s-device-stat-news 2024-10-16T13:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/men-and-women-process-pain-differently-study-finds-uc-san-diego-today 2024-10-16T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/men-and-women-process-pain-differently-study-finds-uc-san-diego-today 2024-10-16T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/jaguar-health-launches-fda-approved-oral-mucositis-prescription-product-gelclair-in-the-u-s 2024-10-16T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jaguar-health-launches-fda-approved-oral-mucositis-prescription-product-gelclair-in-the-u-s 2024-10-16T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-expects-new-uk-clinical-trial-regulation-implementation-by-january-2026 2024-10-16T12:32:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-expects-new-uk-clinical-trial-regulation-implementation-by-january-2026 2024-10-16T12:32:19+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-orphan-medicinal-product-designation-for-navenibart-astria 2024-10-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-grants-orphan-medicinal-product-designation-for-navenibart-astria 2024-10-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/theriva-biologics-announces-orphan-medicinal-product-globenewswire 2024-10-16T12:12:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theriva-biologics-announces-orphan-medicinal-product-globenewswire 2024-10-16T12:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/uconn-s-promising-stroke-medicine-one-step-closer-to-clinical-trial-testing 2024-10-16T11:42:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uconn-s-promising-stroke-medicine-one-step-closer-to-clinical-trial-testing 2024-10-16T11:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-highlights-progress-in-cardiac-myosin-modulation-programs-and-global 2024-10-16T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-highlights-progress-in-cardiac-myosin-modulation-programs-and-global 2024-10-16T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude 2024-10-16T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude 2024-10-16T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-for-emerging-high-intensity-focused 2024-10-16T11:34:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-for-emerging-high-intensity-focused 2024-10-16T11:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/cessatech-announces-that-recruitment-has-today-reached-the-halfway-point-for-patient 2024-10-16T11:19:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cessatech-announces-that-recruitment-has-today-reached-the-halfway-point-for-patient 2024-10-16T11:19:36+00:00 weekly 0.7 https://trial.medpath.com/news/ai-tools-revolutionize-cancer-diagnosis-and-treatment-precision-expert-says 2024-10-16T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-tools-revolutionize-cancer-diagnosis-and-treatment-precision-expert-says 2024-10-16T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shilpa-medicare-s-us-customer-gets-fast-track-approval-for-glioblastoma-drug 2024-10-16T10:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shilpa-medicare-s-us-customer-gets-fast-track-approval-for-glioblastoma-drug 2024-10-16T10:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-capvaxivetm-pneumococcal-21-valent-conjugate-vaccine-demonstrates 2024-10-16T10:57:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-capvaxivetm-pneumococcal-21-valent-conjugate-vaccine-demonstrates 2024-10-16T10:57:19+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-published-results-of-analytical-similarity-study-of-biosimilar-candidate-fyb206-and 2024-10-16T10:53:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formycon-published-results-of-analytical-similarity-study-of-biosimilar-candidate-fyb206-and 2024-10-16T10:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/official-seal-of-approval-for-university-of-central-lancashire-s-clinical-trials-unit 2024-10-16T10:50:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/official-seal-of-approval-for-university-of-central-lancashire-s-clinical-trials-unit 2024-10-16T10:50:27+00:00 weekly 0.7 https://trial.medpath.com/news/what-journalists-should-know-before-diving-into-drug-investigations 2024-10-16T09:49:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-journalists-should-know-before-diving-into-drug-investigations 2024-10-16T09:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/servier-steps-up-commitment-to-digital-innovation-for-patients-with-klineo-partnership 2024-10-16T09:20:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/servier-steps-up-commitment-to-digital-innovation-for-patients-with-klineo-partnership 2024-10-16T09:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/efforts-to-increase-diversity-in-cancer-clinical-trials-fall-short-news-medical 2024-10-16T09:10:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efforts-to-increase-diversity-in-cancer-clinical-trials-fall-short-news-medical 2024-10-16T09:10:38+00:00 weekly 0.7 https://trial.medpath.com/news/who-suspends-approval-process-for-russian-sputnik-v-vaccine-telegrafi 2024-10-16T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-suspends-approval-process-for-russian-sputnik-v-vaccine-telegrafi 2024-10-16T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/uk-launches-2-clinical-trials-into-cannabis-and-childhood-epilepsy-but-serious-concerns 2024-10-16T09:05:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-launches-2-clinical-trials-into-cannabis-and-childhood-epilepsy-but-serious-concerns 2024-10-16T09:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-expert-removing-prior-authorization-for-biomarker-testing-could-improve-cancer-survival-rates 2024-10-16T08:49:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-expert-removing-prior-authorization-for-biomarker-testing-could-improve-cancer-survival-rates 2024-10-16T08:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-medical-cannabis-outcomes-study-kicks-off-hemp-gazette 2024-10-16T08:44:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canadian-medical-cannabis-outcomes-study-kicks-off-hemp-gazette 2024-10-16T08:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-gains-4-on-filing-for-dcgi-s-approval-for-its-insulin-injection-news-on-markets 2024-10-16T08:20:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-gains-4-on-filing-for-dcgi-s-approval-for-its-insulin-injection-news-on-markets 2024-10-16T08:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/bioversys-announces-last-patient-last-visit-in-bv100-phase-2-clinical-trial-in-ventilator 2024-10-16T08:14:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioversys-announces-last-patient-last-visit-in-bv100-phase-2-clinical-trial-in-ventilator 2024-10-16T08:14:11+00:00 weekly 0.7 https://trial.medpath.com/news/bostongene-and-sarah-cannon-research-institute-collaborate-to-accelerate-the-biospace 2024-10-16T07:37:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bostongene-and-sarah-cannon-research-institute-collaborate-to-accelerate-the-biospace 2024-10-16T07:37:01+00:00 weekly 0.7 https://trial.medpath.com/news/avs-enrolls-first-patient-in-u-s-pivotal-intravascular-lithotripsy-study-biospace 2024-10-16T07:14:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avs-enrolls-first-patient-in-u-s-pivotal-intravascular-lithotripsy-study-biospace 2024-10-16T07:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/how-genes-determine-the-effectiveness-of-diets-in-irritable-bowel-syndrome 2024-10-16T07:13:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-genes-determine-the-effectiveness-of-diets-in-irritable-bowel-syndrome 2024-10-16T07:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/language-barriers-in-clinical-research-trial-term-deters-patient-participation-study-finds 2024-10-16T06:51:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/language-barriers-in-clinical-research-trial-term-deters-patient-participation-study-finds 2024-10-16T06:51:23+00:00 weekly 0.7 https://trial.medpath.com/news/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary 2024-10-16T06:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary 2024-10-16T06:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/focus-on-long-term-protection-european-biotechnology-magazine 2024-10-16T06:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/focus-on-long-term-protection-european-biotechnology-magazine 2024-10-16T06:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/rising-costs-and-coverage-challenges-shape-anti-obesity-medication-landscape-in-us 2024-10-16T05:30:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-costs-and-coverage-challenges-shape-anti-obesity-medication-landscape-in-us 2024-10-16T05:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-that-tagrisso-r-plus-orpathys-r-demonstrated-high-clinically 2024-10-16T05:26:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-announces-that-tagrisso-r-plus-orpathys-r-demonstrated-high-clinically 2024-10-16T05:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/stampede2-trial-explores-combination-niraparib-and-abiraterone-in-mhspc-urotoday 2024-10-16T05:05:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stampede2-trial-explores-combination-niraparib-and-abiraterone-in-mhspc-urotoday 2024-10-16T05:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-affirmed-for-novocure-as-fda-approval-expands-optune-s-market-potential 2024-10-16T04:43:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-affirmed-for-novocure-as-fda-approval-expands-optune-s-market-potential 2024-10-16T04:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/oncodesign-precision-medicine-s-a-inside-information-other-news-releases 2024-10-16T03:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncodesign-precision-medicine-s-a-inside-information-other-news-releases 2024-10-16T03:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-files-patent-lawsuit-against-moderna-over-mrna-vaccine-technology 2024-10-16T02:59:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-files-patent-lawsuit-against-moderna-over-mrna-vaccine-technology 2024-10-16T02:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharm-advances-6-new-drugs-into-clinical-trials-for-hypertension-diabetes-and-cancer-kbr 2024-10-16T02:43:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharm-advances-6-new-drugs-into-clinical-trials-for-hypertension-diabetes-and-cancer-kbr 2024-10-16T02:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/annexon-to-present-new-phase-2-archer-data-for-anx007-in-dry-amd-patients-with-less 2024-10-16T02:23:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annexon-to-present-new-phase-2-archer-data-for-anx007-in-dry-amd-patients-with-less 2024-10-16T02:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/nyrada-gears-up-for-phase-i-clinical-trials-sharecafe 2024-10-16T00:45:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nyrada-gears-up-for-phase-i-clinical-trials-sharecafe 2024-10-16T00:45:21+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-forms-scientific-and-patient-advisory-board-biospace 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-forms-scientific-and-patient-advisory-board-biospace 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-efficacy-of-the-blood-stage-malaria-vaccine-rh5 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-and-efficacy-of-the-blood-stage-malaria-vaccine-rh5 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xyra-announces-fda-label-guidance-for-managing-atrial-fibrillation-with-budiodarone-and-wearable-monitoring-devices 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xyra-announces-fda-label-guidance-for-managing-atrial-fibrillation-with-budiodarone-and-wearable-monitoring-devices 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-sallman-on-the-significance-of-the-fda-approval-of-luspatercept-for-lower-risk-mds 2024-10-15T22:32:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-sallman-on-the-significance-of-the-fda-approval-of-luspatercept-for-lower-risk-mds 2024-10-15T22:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102 2024-10-15T22:10:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102 2024-10-15T22:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/catalyst-orthoscience-announces-fda-510-k-clearance-for-shoulder-fracture-system-and 2024-10-15T21:56:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/catalyst-orthoscience-announces-fda-510-k-clearance-for-shoulder-fracture-system-and 2024-10-15T21:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/imforte-shows-benefits-of-lurbinectedin-atezolizumab-in-es-sclc-targeted-oncology 2024-10-15T21:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imforte-shows-benefits-of-lurbinectedin-atezolizumab-in-es-sclc-targeted-oncology 2024-10-15T21:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-optune-lua-for-metastatic-nsclc-after-platinum-based-chemotherapy 2024-10-15T21:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-optune-lua-for-metastatic-nsclc-after-platinum-based-chemotherapy 2024-10-15T21:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/meiragtx-looks-to-a-phase-iii-in-parkinson-s-bioworld 2024-10-15T21:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meiragtx-looks-to-a-phase-iii-in-parkinson-s-bioworld 2024-10-15T21:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/capmatinib-in-met-exon-14-mutated-nsclc-the-asco-post 2024-10-15T20:59:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capmatinib-in-met-exon-14-mutated-nsclc-the-asco-post 2024-10-15T20:59:19+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102-stock-titan 2024-10-15T20:41:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102-stock-titan 2024-10-15T20:41:21+00:00 weekly 0.7 https://trial.medpath.com/news/uropot-study-protocol-for-a-randomized-double-blind-phase-i-ii-trial-for-metabolism-based 2024-10-15T20:34:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uropot-study-protocol-for-a-randomized-double-blind-phase-i-ii-trial-for-metabolism-based 2024-10-15T20:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-s-cold-calling-cgt-space-at-a-critical-crossroads-pharmaceutical-executive 2024-10-15T20:08:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-s-cold-calling-cgt-space-at-a-critical-crossroads-pharmaceutical-executive 2024-10-15T20:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/eu-accelerated-assessment-tracker-insights-citeline 2024-10-15T19:41:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-accelerated-assessment-tracker-insights-citeline 2024-10-15T19:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and 2024-10-15T19:27:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and 2024-10-15T19:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/study-resistance-to-antibody-rare-in-rsv-breakthrough-cases-cidrap 2024-10-15T19:19:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-resistance-to-antibody-rare-in-rsv-breakthrough-cases-cidrap 2024-10-15T19:19:36+00:00 weekly 0.7 https://trial.medpath.com/news/ultomiris-over-half-year-helped-most-gmg-patients-in-phase-3-trial 2024-10-15T19:05:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultomiris-over-half-year-helped-most-gmg-patients-in-phase-3-trial 2024-10-15T19:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-heparin-link-two-phases-of-alzheimer-s-damage-prion-disease-testing 2024-10-15T18:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-heparin-link-two-phases-of-alzheimer-s-damage-prion-disease-testing 2024-10-15T18:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-drug-rk-33-shows-promise-in-treating-breast-cancer-bone-metastasis 2024-10-15T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experimental-drug-rk-33-shows-promise-in-treating-breast-cancer-bone-metastasis 2024-10-15T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/immune-profiles-forecast-immunotherapy-side-effects-drug-discovery-and-development 2024-10-15T17:49:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-profiles-forecast-immunotherapy-side-effects-drug-discovery-and-development 2024-10-15T17:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/18f-rhpsma-7-3-pet-mri-demonstrates-high-detection-in-recurrent-prostate-cancer-urology-times 2024-10-15T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/18f-rhpsma-7-3-pet-mri-demonstrates-high-detection-in-recurrent-prostate-cancer-urology-times 2024-10-15T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/why-are-we-still-seeing-gaps-in-women-s-heart-care 2024-10-15T17:23:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-are-we-still-seeing-gaps-in-women-s-heart-care 2024-10-15T17:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/lyka-s-patent-pending-drug-pregabalin-gel-8-w-w-receives-approval-from-cdsco 2024-10-15T17:17:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyka-s-patent-pending-drug-pregabalin-gel-8-w-w-receives-approval-from-cdsco 2024-10-15T17:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/eye-on-pharma-aflibercept-legal-drama-pbm-humira-biosimilars-denosumab-regulatory-review 2024-10-15T17:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eye-on-pharma-aflibercept-legal-drama-pbm-humira-biosimilars-denosumab-regulatory-review 2024-10-15T17:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/allyx-therapeutics-awarded-3-3-million-nih-grant-to-globenewswire 2024-10-15T17:06:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allyx-therapeutics-awarded-3-3-million-nih-grant-to-globenewswire 2024-10-15T17:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-gets-fda-approval-for-meningococcal-vaccine-manila-standard 2024-10-15T16:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-gets-fda-approval-for-meningococcal-vaccine-manila-standard 2024-10-15T16:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/lyra-therapeutics-fully-enrolls-pivotal-phase-3-enlighten-2-globenewswire 2024-10-15T15:54:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyra-therapeutics-fully-enrolls-pivotal-phase-3-enlighten-2-globenewswire 2024-10-15T15:54:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-long-term-laser-treatment-for-inflammatory-acne-vulgaris-hcplive 2024-10-15T15:51:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-long-term-laser-treatment-for-inflammatory-acne-vulgaris-hcplive 2024-10-15T15:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/intermountain-medical-center-first-in-nation-to-use-fda-approved-device-to-treat-life 2024-10-15T15:49:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intermountain-medical-center-first-in-nation-to-use-fda-approved-device-to-treat-life 2024-10-15T15:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-a-mobile-health-intervention-based-on-a-multitheoretical-model-of-health-behavior 2024-10-15T15:38:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effects-of-a-mobile-health-intervention-based-on-a-multitheoretical-model-of-health-behavior 2024-10-15T15:38:53+00:00 weekly 0.7 https://trial.medpath.com/news/healix-study-aims-to-reduce-cervical-cancer-rates-and-health-disparities-uc-davis-health 2024-10-15T15:29:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healix-study-aims-to-reduce-cervical-cancer-rates-and-health-disparities-uc-davis-health 2024-10-15T15:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/shining-new-light-on-breast-cancer-cells-mass-general-giving 2024-10-15T15:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shining-new-light-on-breast-cancer-cells-mass-general-giving 2024-10-15T15:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-invests-in-molecular-glue-jazz-meiragtx-shares-rise-on-drug-data-biopharma-dive 2024-10-15T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-invests-in-molecular-glue-jazz-meiragtx-shares-rise-on-drug-data-biopharma-dive 2024-10-15T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/msk-research-highlights-october-15-2024-memorial-sloan-kettering-cancer-center 2024-10-15T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msk-research-highlights-october-15-2024-memorial-sloan-kettering-cancer-center 2024-10-15T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/uk-plans-weight-loss-drug-trials-to-get-people-back-to-work-dw 2024-10-15T15:07:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-plans-weight-loss-drug-trials-to-get-people-back-to-work-dw 2024-10-15T15:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-market-size-to-worth-usd-85-37-billion-by-2033-straits-research 2024-10-15T15:02:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-market-size-to-worth-usd-85-37-billion-by-2033-straits-research 2024-10-15T15:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/ventyx-biosciences-presents-new-52-week-results-from-the-phase-2-trial-of-vtx002 2024-10-15T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ventyx-biosciences-presents-new-52-week-results-from-the-phase-2-trial-of-vtx002 2024-10-15T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/pharmamar-announces-positive-and-statistically-significant-overall-survival-and-markets-data 2024-10-15T14:36:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmamar-announces-positive-and-statistically-significant-overall-survival-and-markets-data 2024-10-15T14:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-open-label-dose-escalation-trial-with-expansion-cohorts-to-evaluate-the 2024-10-15T14:35:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-open-label-dose-escalation-trial-with-expansion-cohorts-to-evaluate-the 2024-10-15T14:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/predicting-response-to-rtms-in-mdd-psychiatric-times 2024-10-15T14:33:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/predicting-response-to-rtms-in-mdd-psychiatric-times 2024-10-15T14:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/keynote-811-pembrolizumab-combination-in-first-line-setting-improves-overall-survival 2024-10-15T14:22:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keynote-811-pembrolizumab-combination-in-first-line-setting-improves-overall-survival 2024-10-15T14:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/laura-j-van-t-veer-phd-honored-with-2024-william-l-mcguire-memorial-lecture-award 2024-10-15T14:18:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/laura-j-van-t-veer-phd-honored-with-2024-william-l-mcguire-memorial-lecture-award 2024-10-15T14:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/chiglitazar-for-the-treatment-of-mash-phase-ii-clinical-study-selected-for-oral-presentation 2024-10-15T14:17:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chiglitazar-for-the-treatment-of-mash-phase-ii-clinical-study-selected-for-oral-presentation 2024-10-15T14:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-regains-compliance-with-nasdaq-listing-standards-alzn-stock-news 2024-10-15T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzamend-neuro-regains-compliance-with-nasdaq-listing-standards-alzn-stock-news 2024-10-15T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/trop2-offers-attractive-therapeutic-target-in-breast-cancer-and-other-solid-tumors-onclive 2024-10-15T14:07:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trop2-offers-attractive-therapeutic-target-in-breast-cancer-and-other-solid-tumors-onclive 2024-10-15T14:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/remote-monitoring-of-rheumatoid-arthritis-remora-study-protocol-for-a-stepped-wedge-trials 2024-10-15T13:47:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remote-monitoring-of-rheumatoid-arthritis-remora-study-protocol-for-a-stepped-wedge-trials 2024-10-15T13:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/government-to-spend-ps300m-on-weight-loss-drug-trials-the-times 2024-10-15T13:41:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/government-to-spend-ps300m-on-weight-loss-drug-trials-the-times 2024-10-15T13:41:04+00:00 weekly 0.7 https://trial.medpath.com/news/ocular-therapeutixtm-announces-accelerated-timelines-for-sol-1-registrational-trial-biospace 2024-10-15T13:40:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocular-therapeutixtm-announces-accelerated-timelines-for-sol-1-registrational-trial-biospace 2024-10-15T13:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/genprex-receives-safety-review-committee-approval-to-advance-to-highest-dose-group-in 2024-10-15T13:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genprex-receives-safety-review-committee-approval-to-advance-to-highest-dose-group-in 2024-10-15T13:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-omvoh-beats-j-j-s-stelara-in-head-to-head-phase-iii-crohn-s-disease-trial 2024-10-15T13:33:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-omvoh-beats-j-j-s-stelara-in-head-to-head-phase-iii-crohn-s-disease-trial 2024-10-15T13:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/immune-based-subgroups-uncover-diverse-tumor-immunogenicity-and-implications-for-frontiers 2024-10-15T13:21:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-based-subgroups-uncover-diverse-tumor-immunogenicity-and-implications-for-frontiers 2024-10-15T13:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/october-15-2024-case-study-describes-a-reassessment-of-sample-size-in-an-ongoing 2024-10-15T13:17:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-15-2024-case-study-describes-a-reassessment-of-sample-size-in-an-ongoing 2024-10-15T13:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-s-investigational-drug-candidate-lp-184-receives-fast-track-yahoo-finance 2024-10-15T13:11:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantern-pharma-s-investigational-drug-candidate-lp-184-receives-fast-track-yahoo-finance 2024-10-15T13:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-dosing-of-first-patient-in-phase-i-ii-clinical-trial-of-amt-162-for-the 2024-10-15T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-dosing-of-first-patient-in-phase-i-ii-clinical-trial-of-amt-162-for-the 2024-10-15T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/how-will-manchester-weight-loss-drug-trial-for-unemployed-work-bbc 2024-10-15T13:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-will-manchester-weight-loss-drug-trial-for-unemployed-work-bbc 2024-10-15T13:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-research-launches-decentralized-clinical-trial-in-parkinson-s-disease 2024-10-15T12:37:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-research-launches-decentralized-clinical-trial-in-parkinson-s-disease 2024-10-15T12:37:43+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-granted-orphan-drug-designation-for-imm-1-104-globenewswire 2024-10-15T12:35:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuneering-granted-orphan-drug-designation-for-imm-1-104-globenewswire 2024-10-15T12:35:01+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-poster-presentation-of-novel-thio-prodrugs-at-ena-2024 2024-10-15T12:23:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-poster-presentation-of-novel-thio-prodrugs-at-ena-2024 2024-10-15T12:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-clinical-advances-across-hepatitis-delta-and-hepatitis-b 2024-10-15T12:19:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-clinical-advances-across-hepatitis-delta-and-hepatitis-b 2024-10-15T12:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimer-s-studies-paving-the-way-to-ndas 2024-10-15T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimer-s-studies-paving-the-way-to-ndas 2024-10-15T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-provides-phase-3-clinical-engagement-update-in-metastatic-breast-cancer-pivotal-study 2024-10-15T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/briacell-provides-phase-3-clinical-engagement-update-in-metastatic-breast-cancer-pivotal-study 2024-10-15T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-anlotinib-hydrochloride-in-advanced-gastric-adenocarcinoma-and-nature 2024-10-15T12:06:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-anlotinib-hydrochloride-in-advanced-gastric-adenocarcinoma-and-nature 2024-10-15T12:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/contego-medical-s-neuroguard-iep-system-receives-fda-approval-for-carotid-prweb 2024-10-15T12:02:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contego-medical-s-neuroguard-iep-system-receives-fda-approval-for-carotid-prweb 2024-10-15T12:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/hoth-therapeutics-awarded-key-us-patent-for-groundbreaking-alzheimer-s-treatment-and 2024-10-15T11:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hoth-therapeutics-awarded-key-us-patent-for-groundbreaking-alzheimer-s-treatment-and 2024-10-15T11:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/airway-therapeutics-to-launch-a-multinational-phase-3-trial-of-zelpultide-alfa-for-preterm 2024-10-15T11:01:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/airway-therapeutics-to-launch-a-multinational-phase-3-trial-of-zelpultide-alfa-for-preterm 2024-10-15T11:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/pheast-partners-with-lonza-to-produce-cancer-gobbling-cd24-drug-bioprocess-international 2024-10-15T10:50:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pheast-partners-with-lonza-to-produce-cancer-gobbling-cd24-drug-bioprocess-international 2024-10-15T10:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-spectralis-flex-module-expanding-access-to-advanced-biospace 2024-10-15T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-clearance-for-spectralis-flex-module-expanding-access-to-advanced-biospace 2024-10-15T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/wearable-tech-study-delivers-strong-results-for-cmt-clinical-trials-ein-presswire 2024-10-15T10:23:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wearable-tech-study-delivers-strong-results-for-cmt-clinical-trials-ein-presswire 2024-10-15T10:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/zeo-scientifix-a-leading-south-florida-biotechnology-company-launches-regenerative 2024-10-15T10:17:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zeo-scientifix-a-leading-south-florida-biotechnology-company-launches-regenerative 2024-10-15T10:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/ananda-scientific-announces-a-clinical-trial-evaluating-nantheiatm-atl5-in-the-treatment 2024-10-15T10:15:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ananda-scientific-announces-a-clinical-trial-evaluating-nantheiatm-atl5-in-the-treatment 2024-10-15T10:15:23+00:00 weekly 0.7 https://trial.medpath.com/news/ema-drafts-concept-paper-for-future-radiopharmaceuticals-guideline-raps 2024-10-15T10:05:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-drafts-concept-paper-for-future-radiopharmaceuticals-guideline-raps 2024-10-15T10:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-applies-for-eu-approval-for-drug-to-treat-menopausal-symptoms-marketscreener 2024-10-15T09:38:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-applies-for-eu-approval-for-drug-to-treat-menopausal-symptoms-marketscreener 2024-10-15T09:38:55+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-diamond-phase-3-program-in-diabetic-macular-edema-globenewswire 2024-10-15T08:05:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oculis-diamond-phase-3-program-in-diabetic-macular-edema-globenewswire 2024-10-15T08:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/adolescent-drug-overdose-deaths-show-first-decline-since-pandemic-onset 2024-10-15T07:13:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adolescent-drug-overdose-deaths-show-first-decline-since-pandemic-onset 2024-10-15T07:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/dr-voss-on-the-clinical-significance-of-the-keynote-564-study-in-ccrcc-onclive 2024-10-15T07:07:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-voss-on-the-clinical-significance-of-the-keynote-564-study-in-ccrcc-onclive 2024-10-15T07:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/italy-italian-medicine-agency-new-guidelines-on-clinical-trials-global-compliance-news 2024-10-15T06:52:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/italy-italian-medicine-agency-new-guidelines-on-clinical-trials-global-compliance-news 2024-10-15T06:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/stratosphere-2-study-protocol-for-a-response-adaptive-randomised-placebo-controlled-trials 2024-10-15T06:28:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stratosphere-2-study-protocol-for-a-response-adaptive-randomised-placebo-controlled-trials 2024-10-15T06:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/penumbra-inc-announces-completion-of-thunder-ide-study-enrollment-for-acute-ischemic-stroke 2024-10-15T06:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/penumbra-inc-announces-completion-of-thunder-ide-study-enrollment-for-acute-ischemic-stroke 2024-10-15T06:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-completes-recruitment-of-its-ares-phase-3-trial-for-maat013-to-treat-acute 2024-10-15T05:36:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maat-pharma-completes-recruitment-of-its-ares-phase-3-trial-for-maat013-to-treat-acute 2024-10-15T05:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/experts-discuss-treatment-strategies-for-advanced-rcc-focus-on-nivolumab-ipilimumab-combination 2024-10-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-discuss-treatment-strategies-for-advanced-rcc-focus-on-nivolumab-ipilimumab-combination 2024-10-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chest-2024-major-breakthroughs-in-copd-treatment-and-pulmonary-embolism-management-unveiled 2024-10-15T04:55:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chest-2024-major-breakthroughs-in-copd-treatment-and-pulmonary-embolism-management-unveiled 2024-10-15T04:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/forbion-secures-eur2-billion-in-landmark-biotech-investment-funds 2024-10-15T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/forbion-secures-eur2-billion-in-landmark-biotech-investment-funds 2024-10-15T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-tremfya-and-carvykti-show-strong-growth-as-company-braces-for-stelara-biosimilar-competition 2024-10-15T04:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-tremfya-and-carvykti-show-strong-growth-as-company-braces-for-stelara-biosimilar-competition 2024-10-15T04:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grapples-with-ai-ml-medical-device-oversight-regulatory-gaps-and-bias-concerns-emerge 2024-10-15T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grapples-with-ai-ml-medical-device-oversight-regulatory-gaps-and-bias-concerns-emerge 2024-10-15T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drugs-and-clinical-trials-amendment-rules-2024-mondaq 2024-10-15T02:12:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drugs-and-clinical-trials-amendment-rules-2024-mondaq 2024-10-15T02:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/pharmabcine-announces-safety-approval-for-4mg-single-dose-cohort-in-phase-1-clinical 2024-10-15T02:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmabcine-announces-safety-approval-for-4mg-single-dose-cohort-in-phase-1-clinical 2024-10-15T02:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/paratek-pharmaceuticals-announces-presentation-of-several-new-studies-of-nuzyra-biospace 2024-10-15T01:01:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paratek-pharmaceuticals-announces-presentation-of-several-new-studies-of-nuzyra-biospace 2024-10-15T01:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/plasma-proteomic-and-polygenic-profiling-improve-risk-stratification-and-personalized 2024-10-15T00:16:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plasma-proteomic-and-polygenic-profiling-improve-risk-stratification-and-personalized 2024-10-15T00:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/tenecteplase-plus-thrombectomy-improves-stroke-outcomes-in-chinese-trial 2024-10-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenecteplase-plus-thrombectomy-improves-stroke-outcomes-in-chinese-trial 2024-10-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/taysha-seeks-to-overturn-natural-history-trends-with-rett-syndrome-gene-therapy-in-dual 2024-10-14T22:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taysha-seeks-to-overturn-natural-history-trends-with-rett-syndrome-gene-therapy-in-dual 2024-10-14T22:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/kod-kodiak-sciences-inc-latest-stock-news-market-updates 2024-10-14T21:56:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kod-kodiak-sciences-inc-latest-stock-news-market-updates 2024-10-14T21:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/dr-boreham-s-crucible-can-this-small-aussie-company-meet-mnd-s-sizeable-need 2024-10-14T19:39:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-boreham-s-crucible-can-this-small-aussie-company-meet-mnd-s-sizeable-need 2024-10-14T19:39:58+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-established-pharmaceutical-companies-in-bringing-cell-therapy-to-cgtlive-r 2024-10-14T19:34:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-role-of-established-pharmaceutical-companies-in-bringing-cell-therapy-to-cgtlive-r 2024-10-14T19:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/selinexor-paves-the-way-for-more-affordable-effective-treatment-options-in-myelofibrosis 2024-10-14T19:07:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/selinexor-paves-the-way-for-more-affordable-effective-treatment-options-in-myelofibrosis 2024-10-14T19:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/sotagliflozin-in-patients-with-type-1-diabetes-and-ckd-to-be-discussed-at-october-fda 2024-10-14T18:49:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sotagliflozin-in-patients-with-type-1-diabetes-and-ckd-to-be-discussed-at-october-fda 2024-10-14T18:49:08+00:00 weekly 0.7 https://trial.medpath.com/news/electroconvulsive-therapy-for-the-treatment-of-dementia-symptoms-psychiatric-times 2024-10-14T18:27:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/electroconvulsive-therapy-for-the-treatment-of-dementia-symptoms-psychiatric-times 2024-10-14T18:27:50+00:00 weekly 0.7 https://trial.medpath.com/news/dr-john-byrd-87-and-dr-tom-goodwin-credited-with-early-work-on-cancer-drug-recently 2024-10-14T18:05:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-john-byrd-87-and-dr-tom-goodwin-credited-with-early-work-on-cancer-drug-recently 2024-10-14T18:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ceftobiprole-medocaril-sodium-for-3-indications-drug-topics 2024-10-14T17:43:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ceftobiprole-medocaril-sodium-for-3-indications-drug-topics 2024-10-14T17:43:34+00:00 weekly 0.7 https://trial.medpath.com/news/the-u-s-fda-grants-fast-track-designation-to-coherent-biopharma-s-cbp-1008 2024-10-14T17:18:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-u-s-fda-grants-fast-track-designation-to-coherent-biopharma-s-cbp-1008 2024-10-14T17:18:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-facing-pressure-to-review-position-on-zepbound-mounjaro-shortage-biopharma-dive 2024-10-14T17:17:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-facing-pressure-to-review-position-on-zepbound-mounjaro-shortage-biopharma-dive 2024-10-14T17:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-teams-with-the-big-ten-conference-to-raise-blood-pharmaceutical-executive 2024-10-14T17:17:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-teams-with-the-big-ten-conference-to-raise-blood-pharmaceutical-executive 2024-10-14T17:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/recon-fda-may-rethink-shortage-listing-for-eli-lilly-s-tirzepatide-raps 2024-10-14T16:40:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-fda-may-rethink-shortage-listing-for-eli-lilly-s-tirzepatide-raps 2024-10-14T16:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-therapy-may-reduce-suicidal-ideation-risk-for-adolescents-with-obesity-healio 2024-10-14T15:54:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-therapy-may-reduce-suicidal-ideation-risk-for-adolescents-with-obesity-healio 2024-10-14T15:54:35+00:00 weekly 0.7 https://trial.medpath.com/news/collaboration-to-support-clinical-development-of-psma-targeting-theranostics-in-japan 2024-10-14T15:50:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/collaboration-to-support-clinical-development-of-psma-targeting-theranostics-in-japan 2024-10-14T15:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/anti-obesity-drugs-tied-to-lower-risk-of-suicidal-thoughts-or-attempts-among-young-people 2024-10-14T15:24:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anti-obesity-drugs-tied-to-lower-risk-of-suicidal-thoughts-or-attempts-among-young-people 2024-10-14T15:24:17+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-and-zydus-lifesciences-initiate-second-phase-proof-of-concept-trial-for-desidustat-in 2024-10-14T15:14:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-and-zydus-lifesciences-initiate-second-phase-proof-of-concept-trial-for-desidustat-in 2024-10-14T15:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/cf-may-have-stifled-her-before-but-now-she-can-laugh-sanford-health-news 2024-10-14T15:04:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cf-may-have-stifled-her-before-but-now-she-can-laugh-sanford-health-news 2024-10-14T15:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-october-2024-research-roundup-first10em 2024-10-14T14:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-october-2024-research-roundup-first10em 2024-10-14T14:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-directions-in-all-cml-and-cll-treatment-the-asco-post 2024-10-14T14:52:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-directions-in-all-cml-and-cll-treatment-the-asco-post 2024-10-14T14:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/tpst-stock-touches-52-week-low-at-0-92-amid-market-challenges-investing-com 2024-10-14T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tpst-stock-touches-52-week-low-at-0-92-amid-market-challenges-investing-com 2024-10-14T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/fianlimab-combo-shows-activity-in-advanced-melanoma-subtypes-cancer-network 2024-10-14T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fianlimab-combo-shows-activity-in-advanced-melanoma-subtypes-cancer-network 2024-10-14T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/aiims-bathinda-makes-breakthrough-in-stem-cell-therapy-research-for-heart-ailments 2024-10-14T14:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aiims-bathinda-makes-breakthrough-in-stem-cell-therapy-research-for-heart-ailments 2024-10-14T14:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/biofrontera-inc-announces-database-lock-of-phase-3-study-of-ameluz-globenewswire 2024-10-14T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biofrontera-inc-announces-database-lock-of-phase-3-study-of-ameluz-globenewswire 2024-10-14T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/mixed-active-metabolites-of-the-snp-6-series-of-novel-compounds-mitigate-metabolic 2024-10-14T14:29:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mixed-active-metabolites-of-the-snp-6-series-of-novel-compounds-mitigate-metabolic 2024-10-14T14:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/ischemic-stroke-drug-pipeline-research-report-2024-yahoo-finance 2024-10-14T14:27:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ischemic-stroke-drug-pipeline-research-report-2024-yahoo-finance 2024-10-14T14:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-but-stock-sends-mixed-signals 2024-10-14T14:19:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-but-stock-sends-mixed-signals 2024-10-14T14:19:48+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-stock-falls-as-analyst-warns-that-hype-around-obesity-drug-is-baked-in-morningstar 2024-10-14T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-s-stock-falls-as-analyst-warns-that-hype-around-obesity-drug-is-baked-in-morningstar 2024-10-14T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/dr-tao-on-the-efficacy-of-avelumab-cetuximab-radiotherapy-in-cisplain-eligibile-vs 2024-10-14T14:16:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-tao-on-the-efficacy-of-avelumab-cetuximab-radiotherapy-in-cisplain-eligibile-vs 2024-10-14T14:16:15+00:00 weekly 0.7 https://trial.medpath.com/news/chemoimmunotherapy-is-at-the-forefront-of-the-perioperative-nsclc-paradigm-onclive 2024-10-14T14:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemoimmunotherapy-is-at-the-forefront-of-the-perioperative-nsclc-paradigm-onclive 2024-10-14T14:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal-significantly-enhancing 2024-10-14T13:55:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal-significantly-enhancing 2024-10-14T13:55:45+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-doses-first-subject-in-phase-i-solid-tumour-trial 2024-10-14T13:43:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-doses-first-subject-in-phase-i-solid-tumour-trial 2024-10-14T13:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/lifevantage-introduces-the-mindbody-glp-1-systemtm-transforming-weight-management 2024-10-14T13:22:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifevantage-introduces-the-mindbody-glp-1-systemtm-transforming-weight-management 2024-10-14T13:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-lomecel-btm-data-in-alzheimer-s-disease-selected-for-late-breaking-poster 2024-10-14T13:21:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-lomecel-btm-data-in-alzheimer-s-disease-selected-for-late-breaking-poster 2024-10-14T13:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/vivance-completes-pre-pivotal-trial-of-wearable-dialysis-device-kilgore-news-herald 2024-10-14T13:20:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivance-completes-pre-pivotal-trial-of-wearable-dialysis-device-kilgore-news-herald 2024-10-14T13:20:19+00:00 weekly 0.7 https://trial.medpath.com/news/exelixis-and-merck-collaborate-on-cancer-drug-trials-investing-com 2024-10-14T13:20:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exelixis-and-merck-collaborate-on-cancer-drug-trials-investing-com 2024-10-14T13:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-stock-holds-price-target-on-fda-approval-investing-com-uk 2024-10-14T13:17:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relay-therapeutics-stock-holds-price-target-on-fda-approval-investing-com-uk 2024-10-14T13:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/early-phase-oncology-clinical-trials-unit-opened-at-mater-medical-independent 2024-10-14T13:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-phase-oncology-clinical-trials-unit-opened-at-mater-medical-independent 2024-10-14T13:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-research-milestone-in-billings-means-hope-for-montana-residents 2024-10-14T13:05:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-research-milestone-in-billings-means-hope-for-montana-residents 2024-10-14T13:05:37+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-of-the-effects-of-postbiotic-supplementation-on-inflammation-oxidative-stress 2024-10-14T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-of-the-effects-of-postbiotic-supplementation-on-inflammation-oxidative-stress 2024-10-14T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/nexalin-technology-appoints-carolyn-shelton-as-senior-vice-globenewswire 2024-10-14T12:55:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nexalin-technology-appoints-carolyn-shelton-as-senior-vice-globenewswire 2024-10-14T12:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-to-participate-in-panel-at-bio-investor-forum-2024-kilgore-news-herald 2024-10-14T12:42:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halia-therapeutics-to-participate-in-panel-at-bio-investor-forum-2024-kilgore-news-herald 2024-10-14T12:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-biomarker-and-modeling-approach-to-support-dose-finding-for-bi-836880-a 2024-10-14T12:31:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-biomarker-and-modeling-approach-to-support-dose-finding-for-bi-836880-a 2024-10-14T12:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-reports-one-year-histologic-outcomes-in-phase-3-study-of-mirikizumab-compared-to 2024-10-14T12:26:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-reports-one-year-histologic-outcomes-in-phase-3-study-of-mirikizumab-compared-to 2024-10-14T12:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/belite-bio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-14T12:26:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belite-bio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-14T12:26:07+00:00 weekly 0.7 https://trial.medpath.com/news/cepi-to-initiate-phase-ii-trials-of-a-rift-valley-fever-vaccine-in-kenya 2024-10-14T12:19:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cepi-to-initiate-phase-ii-trials-of-a-rift-valley-fever-vaccine-in-kenya 2024-10-14T12:19:32+00:00 weekly 0.7 https://trial.medpath.com/news/spyre-therapeutics-announces-expected-acceleration-of-spy003-il-23p19-markets-data 2024-10-14T12:17:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spyre-therapeutics-announces-expected-acceleration-of-spy003-il-23p19-markets-data 2024-10-14T12:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/national-medical-products-administration-accepts-grand-pharmaceutical-group-limited-s 2024-10-14T12:13:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-medical-products-administration-accepts-grand-pharmaceutical-group-limited-s 2024-10-14T12:13:21+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-shows-efficacy-safety-of-car-t-cell-therapy-in-r-r-mantle-cell-lymphoma 2024-10-14T12:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-shows-efficacy-safety-of-car-t-cell-therapy-in-r-r-mantle-cell-lymphoma 2024-10-14T12:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/global-protac-therapy-market-clinical-trials-drug-approval-insight 2024-10-14T12:07:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-protac-therapy-market-clinical-trials-drug-approval-insight 2024-10-14T12:07:38+00:00 weekly 0.7 https://trial.medpath.com/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m11d1-in-relapsed 2024-10-14T12:05:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m11d1-in-relapsed 2024-10-14T12:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-supports-the-long-term-safety-of-sts101-for-acute-treatment-of-migraine 2024-10-14T12:04:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-data-supports-the-long-term-safety-of-sts101-for-acute-treatment-of-migraine 2024-10-14T12:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-makes-2-6b-cash-move-for-longboard-a-month-after-starting-phase-3-in-dravet-syndrome 2024-10-14T11:25:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-makes-2-6b-cash-move-for-longboard-a-month-after-starting-phase-3-in-dravet-syndrome 2024-10-14T11:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/non-viral-crispr-therapy-alleviates-symptoms-in-humanised-mouse-model-of-primary 2024-10-14T11:24:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-viral-crispr-therapy-alleviates-symptoms-in-humanised-mouse-model-of-primary 2024-10-14T11:24:33+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-on-cervical-cancer-treatment-could-cut-deaths-by-40 2024-10-14T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-on-cervical-cancer-treatment-could-cut-deaths-by-40 2024-10-14T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/redhill-biopharma-secures-u-s-government-funding-through-barda-to-advance-stock-titan 2024-10-14T11:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/redhill-biopharma-secures-u-s-government-funding-through-barda-to-advance-stock-titan 2024-10-14T11:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/bausch-lomb-receives-fda-approval-for-envista-r-envytm-full-range-of-vision-intraocular-lens 2024-10-14T11:08:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bausch-lomb-receives-fda-approval-for-envista-r-envytm-full-range-of-vision-intraocular-lens 2024-10-14T11:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-plus-intestinal-zap-therapy-may-eliminate-need-for-insulin-in-type-2-diabetics 2024-10-14T10:06:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-plus-intestinal-zap-therapy-may-eliminate-need-for-insulin-in-type-2-diabetics 2024-10-14T10:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/mater-research-initiates-combined-covid-flu-vaccine-trial 2024-10-14T10:00:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mater-research-initiates-combined-covid-flu-vaccine-trial 2024-10-14T10:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-enhanced-provider-payer-collaboration-to-transform-value-based-oncology-care 2024-10-14T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-call-for-enhanced-provider-payer-collaboration-to-transform-value-based-oncology-care 2024-10-14T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-antibody-drug-conjugates-market-opportunity-globenewswire 2024-10-14T09:57:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bispecific-antibody-drug-conjugates-market-opportunity-globenewswire 2024-10-14T09:57:38+00:00 weekly 0.7